{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:39:10Z","timestamp":1795145950313,"version":"4.10.3"},"reference-count":466,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2025AFB580"],"award-info":[{"award-number":["2025AFB580"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573812"],"award-info":[{"award-number":["82573812"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011291","name":"National Key Laboratory of Science and Technology on Communications","doi-asserted-by":"publisher","award":["2023YFC2705802"],"award-info":[{"award-number":["2023YFC2705802"]}],"id":[{"id":"10.13039\/501100011291","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02924-w","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:02:24Z","timestamp":1785715344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cancer drug response and resistance: molecular mechanisms and combating strategies"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiaoxia","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaochun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-0264","authenticated-orcid":false,"given":"Canhui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2924_CR1","doi-asserted-by":"crossref","unstructured":"Soragni, A. et al. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat. Rev. Cancer 25, 613\u2013633 (2025).","DOI":"10.1038\/s41568-025-00824-9"},{"key":"2924_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell 37, 496\u2013513 (2020).","journal-title":"Cancer Cell"},{"key":"2924_CR3","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"2924_CR4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2023.03.019","volume":"186","author":"JC Madukwe","year":"2023","unstructured":"Madukwe, J. C. Overcoming drug resistance in cancer. Cell 186, 1515\u20131516 (2023).","journal-title":"Cell"},{"key":"2924_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41568-023-00581-7","volume":"23","author":"A Dart","year":"2023","unstructured":"Dart, A. EMT in chemoresistance. Nat. Rev. Cancer 23, 349\u2013349 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2924_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.tem.2025.08.001","volume":"36","author":"M Xu","year":"2025","unstructured":"Xu, M., Yu, Y. & Cao, C. The dual role of taurine in cancer and immune metabolism. Trends Endocrinol. Metab. 36, 878\u2013881 (2025).","journal-title":"Trends Endocrinol. Metab."},{"key":"2924_CR7","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang, A., Miao, K., Sun, H. & Deng, C. X. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J. Biol. Sci. 18, 3019\u20133033 (2022).","journal-title":"Int J. Biol. Sci."},{"key":"2924_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu, M. et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol. Cancer 23, 92 (2024).","journal-title":"Mol. Cancer"},{"key":"2924_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"2924_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306\u2013313 (2012).","journal-title":"Nature"},{"key":"2924_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).","journal-title":"Nat. Commun."},{"key":"2924_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-025-01722-1","volume":"18","author":"X Cheng","year":"2025","unstructured":"Cheng, X. et al. Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance. J. Hematol. Oncol. 18, 70 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2924_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-024-01596-9","volume":"17","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications. J. Hematol. Oncol. 17, 72 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2924_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","volume":"43","author":"C Alix-Panabieres","year":"2025","unstructured":"Alix-Panabieres, C. & Pantel, K. Advances in liquid biopsy: from exploration to practical application. Cancer Cell 43, 161\u2013165 (2025).","journal-title":"Cancer Cell"},{"key":"2924_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01543-7","volume":"21","author":"SN Lone","year":"2022","unstructured":"Lone, S. N. et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol. Cancer 21, 79 (2022).","journal-title":"Mol. Cancer"},{"key":"2924_CR16","doi-asserted-by":"publisher","first-page":"101520","DOI":"10.1016\/j.gendis.2025.101520","volume":"12","author":"M Liu","year":"2025","unstructured":"Liu, M. & Yang, X. Patient-derived xenograft models: current status, challenges, and innovations in cancer research. Genes Dis. 12, 101520 (2025).","journal-title":"Genes Dis."},{"key":"2924_CR17","first-page":"263","volume":"2","author":"E Wang","year":"2022","unstructured":"Wang, E., Xiang, K., Zhang, Y. & Wang, X.-F. Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): new opportunities in establishing faithful pre-clinical cancer models. J. Natl. Cancer Cent. 2, 263\u2013276 (2022).","journal-title":"J. Natl. Cancer Cent."},{"key":"2924_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.apsb.2022.10.002","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang, L., Ye, B., Chen, Z. & Chen, Z. S. Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers. Acta Pharm. Sin. B 13, 982\u2013997 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"2924_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2924_CR20","doi-asserted-by":"publisher","first-page":"103374","DOI":"10.1016\/j.critrevonc.2021.103374","volume":"163","author":"A Addeo","year":"2021","unstructured":"Addeo, A., Friedlaender, A., Banna, G. L. & Weiss, G. J. TMB or not TMB as a biomarker: that is the question. Crit. Rev. Oncol. Hematol. 163, 103374 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2924_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44\u201356 (2019).","journal-title":"Ann. Oncol."},{"key":"2924_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1200\/JCO.2025.43.4_suppl.163","volume":"43","author":"OM Mosalem","year":"2025","unstructured":"Mosalem, O. M. et al. Immunotherapy outcomes in dMMR\/MSI-H and\/or TMB-H metastatic colorectal cancer (CRC) with peritoneal metastases (PM). J. Clin. Oncol. 43, 163\u2013163 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2924_CR23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","volume":"597","author":"JP Robichaux","year":"2021","unstructured":"Robichaux, J. P. et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597, 732\u2013737 (2021).","journal-title":"Nature"},{"key":"2924_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"2924_CR25","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ccell.2023.09.006","volume":"41","author":"M Zhu","year":"2023","unstructured":"Zhu, M. et al. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell 41, 1731\u20131748.e1738 (2023).","journal-title":"Cancer Cell"},{"key":"2924_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"2924_CR27","doi-asserted-by":"publisher","first-page":"107123","DOI":"10.1016\/j.phrs.2024.107123","volume":"202","author":"X Liu","year":"2024","unstructured":"Liu, X., Mei, W., Zhang, P. & Zeng, C. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: clinical challenges and opportunities. Pharm. Res. 202, 107123 (2024).","journal-title":"Pharm. Res."},{"key":"2924_CR28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41588-022-01108-w","volume":"54","author":"X Ma","year":"2022","unstructured":"Ma, X. et al. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nat. Genet. 54, 996\u20131012 (2022).","journal-title":"Nat. Genet."},{"key":"2924_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.molmed.2024.04.017","volume":"30","author":"P Shahrouzi","year":"2024","unstructured":"Shahrouzi, P. et al. Copy number alterations: a catastrophic orchestration of the breast cancer genome. Trends Mol. Med. 30, 750\u2013764 (2024).","journal-title":"Trends Mol. Med."},{"key":"2924_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.acr.2022.12.001","volume":"158","author":"RR Walker","year":"2023","unstructured":"Walker, R. R., Rentia, Z. & Chiappinelli, K. B. Epigenetically programmed resistance to chemo- and immuno-therapies. Adv. Cancer Res. 158, 41\u201371 (2023).","journal-title":"Adv. Cancer Res."},{"key":"2924_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.trecan.2025.11.004","volume":"12","author":"C Cao","year":"2026","unstructured":"Cao, C. Orchestrating tumor-immune epigenetics via SERT-H3Q5ser axis. Trends Cancer 12, 101\u2013104 (2026).","journal-title":"Trends Cancer"},{"key":"2924_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","volume":"595","author":"GK Griffin","year":"2021","unstructured":"Griffin, G. K. et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 595, 309\u2013314 (2021).","journal-title":"Nature"},{"key":"2924_CR33","doi-asserted-by":"publisher","first-page":"102499","DOI":"10.1016\/j.ctrv.2022.102499","volume":"113","author":"DC Ziogas","year":"2023","unstructured":"Ziogas, D. C. et al. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome? Cancer Treat. Rev. 113, 102499 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"2924_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"2924_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202\u2013216 (2016).","journal-title":"Cancer Discov."},{"key":"2924_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01748-4","volume":"22","author":"B Wu","year":"2023","unstructured":"Wu, B., Shi, X., Jiang, M. & Liu, H. Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Mol. Cancer 22, 38 (2023).","journal-title":"Mol. Cancer"},{"key":"2924_CR37","doi-asserted-by":"crossref","unstructured":"Liu, Y., Liang, J., Zhang, Y. & Guo, Q. Drug resistance and tumor immune microenvironment: an overview of current understandings (Review). Int. J. Oncol. 65, 96 (2024).","DOI":"10.3892\/ijo.2024.5684"},{"key":"2924_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01711-w","volume":"22","author":"M Yang","year":"2024","unstructured":"Yang, M. et al. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance. Cell Commun. Signal. 22, 338 (2024).","journal-title":"Cell Commun. Signal."},{"key":"2924_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J. Exp. Clin. Cancer Res. 44, 145 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2924_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100383","volume":"18","author":"M Nabhan","year":"2023","unstructured":"Nabhan, M. et al. Deciphering the tumour immune microenvironment cell by cell. Immunooncol. Technol. 18, 100383 (2023).","journal-title":"Immunooncol. Technol."},{"key":"2924_CR41","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/0008-5472.CAN-23-0025","volume":"83","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. et al. Matrix stiffness triggers lipid metabolic cross-talk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases. Cancer Res. 83, 3577\u20133592 (2023).","journal-title":"Cancer Res."},{"key":"2924_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52394-3","volume":"15","author":"NY Li","year":"2024","unstructured":"Li, N. Y. et al. Basal-to-inflammatory transition and tumor resistance via crosstalk with a pro-inflammatory stromal niche. Nat. Commun. 15, 8134 (2024).","journal-title":"Nat. Commun."},{"key":"2924_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41580-019-0108-4","volume":"20","author":"MM Rinschen","year":"2019","unstructured":"Rinschen, M. M., Ivanisevic, J., Giera, M. & Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. Nat. Rev. Mol. Cell Biol. 20, 353\u2013367 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2924_CR44","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrd.2018.46","volume":"17","author":"J Rautio","year":"2018","unstructured":"Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. 17, 559\u2013587 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2924_CR45","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/jcph.1284","volume":"58","author":"J van den Anker","year":"2018","unstructured":"van den Anker, J., Reed, M. D., Allegaert, K. & Kearns, G. L. Developmental Changes in Pharmacokinetics and Pharmacodynamics. J. Clin. Pharm. 58, S10\u2013S25 (2018).","journal-title":"J. Clin. Pharm."},{"key":"2924_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman, C. A. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin. Pharm. Ther. 114, 51\u201368 (2023).","journal-title":"Clin. Pharm. Ther."},{"key":"2924_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101706","volume":"5","author":"Y Zhong","year":"2024","unstructured":"Zhong, Y. et al. Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma. Cell Rep. Med. 5, 101706 (2024).","journal-title":"Cell Rep. Med."},{"key":"2924_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2025.106036","volume":"203","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Development and validation of a machine learning-based clinical prediction model for monitoring liver injury in patients with pan-cancer receiving immunotherapy. Int. J. Med. Inf. 203, 106036 (2025).","journal-title":"Int. J. Med. Inf."},{"key":"2924_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01488-8","volume":"17","author":"K Nesic","year":"2025","unstructured":"Nesic, K., Parker, P., Swisher, E. M. & Krais, J. J. DNA repair and the contribution to chemotherapy resistance. Genome Med. 17, 62 (2025).","journal-title":"Genome Med."},{"key":"2924_CR50","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.molcel.2019.04.005","volume":"74","author":"X Tu","year":"2019","unstructured":"Tu, X. et al. PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol. Cell 74, 1215\u20131226.e1214 (2019).","journal-title":"Mol. Cell"},{"key":"2924_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06817-0","volume":"15","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Golgi dispersal in cancer stem cells promotes chemoresistance of colorectal cancer via the Golgi stress response. Cell Death Dis. 15, 417 (2024).","journal-title":"Cell Death Dis."},{"key":"2924_CR52","doi-asserted-by":"publisher","first-page":"216623","DOI":"10.1016\/j.canlet.2024.216623","volume":"584","author":"R Damiescu","year":"2024","unstructured":"Damiescu, R., Efferth, T. & Dawood, M. Dysregulation of different modes of programmed cell death by epigenetic modifications and their role in cancer. Cancer Lett. 584, 216623 (2024).","journal-title":"Cancer Lett."},{"key":"2924_CR53","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1126\/science.adh7950","volume":"384","author":"NJ Boon","year":"2024","unstructured":"Boon, N. J. et al. DNA damage induces p53-independent apoptosis through ribosome stalling. Science 384, 785\u2013792 (2024).","journal-title":"Science"},{"key":"2924_CR54","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05838-7","volume":"616","author":"M Debaugnies","year":"2023","unstructured":"Debaugnies, M. et al. RHOJ controls EMT-associated resistance to chemotherapy. Nature 616, 168\u2013175 (2023).","journal-title":"Nature"},{"key":"2924_CR55","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.7150\/thno.103722","volume":"15","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. A novel pathway for stemness propagation and chemoresistance in non-small cell lung cancer via phosphorylated PKM2-loaded small extracellular vesicles. Theranostics 15, 3439\u20133461 (2025).","journal-title":"Theranostics"},{"key":"2924_CR56","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00018-025-05831-5","volume":"82","author":"Y Cui","year":"2025","unstructured":"Cui, Y. et al. Epigenetic regulation by DNA methylation, histone modifications and chromatin remodeling complexes in controlling spermatogenesis and their dysfunction with male infertility. Cell Mol. Life Sci. 82, 343 (2025).","journal-title":"Cell Mol. Life Sci."},{"key":"2924_CR57","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","volume":"55","author":"X Xu","year":"2023","unstructured":"Xu, X. et al. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp. Mol. Med. 55, 1357\u20131370 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2924_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu, R. et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 11, 797 (2020).","journal-title":"Cell Death Dis."},{"key":"2924_CR59","doi-asserted-by":"publisher","first-page":"1079827","DOI":"10.1155\/2020\/1079827","volume":"2020","author":"EL Paton","year":"2020","unstructured":"Paton, E. L., Turner, J. A. & Schlaepfer, I. R. Overcoming resistance to therapies targeting the MAPK pathway in BRAF-mutated tumours. J. Oncol. 2020, 1079827 (2020).","journal-title":"J. Oncol."},{"key":"2924_CR60","doi-asserted-by":"publisher","first-page":"155837","DOI":"10.1016\/j.prp.2025.155837","volume":"267","author":"K Hushmandi","year":"2025","unstructured":"Hushmandi, K. et al. Targeting Wnt signaling in cancer drug resistance: insights from pre-clinical and clinical research. Pathol. Res Pr. 267, 155837 (2025).","journal-title":"Pathol. Res Pr."},{"key":"2924_CR61","first-page":"2037","volume":"16","author":"LS Lu","year":"2012","unstructured":"Lu, L. S. et al. Elevated expression of both MDR1 and MMP-2 genes in metastasized lymph node of invasive ductal breast cancer. Eur. Rev. Med. Pharm. Sci. 16, 2037\u20132043 (2012).","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"2924_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj5705","volume":"16","author":"G Fan","year":"2024","unstructured":"Fan, G. et al. TSPAN8(+) myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. Sci. Transl. Med. 16, eadj5705 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2924_CR63","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.trecan.2026.01.003","volume":"12","author":"C Cao","year":"2026","unstructured":"Cao, C. Nociceptive neuroimmune circuit drives immune evasion. Trends Cancer 12, 212\u2013214 (2026).","journal-title":"Trends Cancer"},{"key":"2924_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"TS Nowicki","year":"2018","unstructured":"Nowicki, T. S., Hu-Lieskovan, S. & Ribas, A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 24, 47\u201353 (2018).","journal-title":"Cancer J."},{"key":"2924_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"2924_CR66","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","volume":"639","author":"M Al Bakir","year":"2025","unstructured":"Al Bakir, M. et al. Clonal driver neoantigen loss under EGFR TKI and immune selection pressures. Nature 639, 1052\u20131059 (2025).","journal-title":"Nature"},{"key":"2924_CR67","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","volume":"10","author":"DY Torrejon","year":"2020","unstructured":"Torrejon, D. Y. et al. Overcoming genetically based resistance mechanisms to PD-1 blockade. Cancer Discov. 10, 1140\u20131157 (2020).","journal-title":"Cancer Discov."},{"key":"2924_CR68","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","volume":"18","author":"S Sun","year":"2025","unstructured":"Sun, S. et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives. J. Hematol. Oncol. 18, 84 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2924_CR69","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat. Rev. Immunol. 25, 353\u2013369 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"2924_CR70","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.ccell.2025.06.012","volume":"43","author":"KK Dijkstra","year":"2025","unstructured":"Dijkstra, K. K. et al. Subclonal immune evasion in non-small cell lung cancer. Cancer Cell 43, 1833\u20131849.e1810 (2025).","journal-title":"Cancer Cell"},{"key":"2924_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely, M. D., Zhang, T. & Chen, L. Resistance mechanisms to Anti-PD cancer immunotherapy. Annu Rev. Immunol. 40, 45\u201374 (2022).","journal-title":"Annu Rev. Immunol."},{"key":"2924_CR72","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","volume":"31","author":"DY Ruan","year":"2025","unstructured":"Ruan, D. Y. et al. The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. Nat. Med. 31, 3037\u20133046 (2025).","journal-title":"Nat. Med."},{"key":"2924_CR73","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","volume":"26","author":"F Huber","year":"2026","unstructured":"Huber, F. & Bassani-Sternberg, M. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development. Nat. Rev. Immunol. 26, 23\u201334 (2026).","journal-title":"Nat. Rev. Immunol."},{"key":"2924_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200978","volume":"33","author":"A Goloudina","year":"2025","unstructured":"Goloudina, A. et al. Shared neoantigens for cancer immunotherapy. Mol. Ther. Oncol. 33, 200978 (2025).","journal-title":"Mol. Ther. Oncol."},{"key":"2924_CR75","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song, J. et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct. Target Ther. 10, 219 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2924_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen, B. H., Ali, B. R. & Elkord, E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol. Cancer 24, 20 (2025).","journal-title":"Mol. Cancer"},{"key":"2924_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915094","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front. Immunol. 13, 915094 (2022).","journal-title":"Front. Immunol."},{"key":"2924_CR78","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","volume":"57","author":"Y Yan","year":"2025","unstructured":"Yan, Y. et al. Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer. Nat. Genet. 57, 126\u2013139 (2025).","journal-title":"Nat. Genet."},{"key":"2924_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42360-w","volume":"14","author":"CON Leung","year":"2023","unstructured":"Leung, C. O. N. et al. Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nat. Commun. 14, 6699 (2023).","journal-title":"Nat. Commun."},{"key":"2924_CR80","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke, J. J. et al. WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers. Clin. Cancer Res. 25, 3074\u20133083 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2924_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202503009","volume":"12","author":"T He","year":"2025","unstructured":"He, T. et al. CXCL6 reshapes lipid metabolism and induces neutrophil extracellular trap formation in cholangiocarcinoma progression and immunotherapy resistance. Adv. Sci. 12, e2503009 (2025).","journal-title":"Adv. Sci."},{"key":"2924_CR82","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s43018-025-01018-w","volume":"6","author":"J Huang","year":"2025","unstructured":"Huang, J. et al. Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nat. Cancer 6, 1676\u20131692 (2025).","journal-title":"Nat. Cancer"},{"key":"2924_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01448-x","volume":"20","author":"SW Chen","year":"2021","unstructured":"Chen, S. W. et al. Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC. Mol. Cancer 20, 144 (2021).","journal-title":"Mol. Cancer"},{"key":"2924_CR84","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai, L. et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 16, 101 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2924_CR85","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2924_CR86","doi-asserted-by":"publisher","first-page":"216661","DOI":"10.1016\/j.canlet.2024.216661","volume":"585","author":"M Cordani","year":"2024","unstructured":"Cordani, M. et al. Immune checkpoints between epithelial-mesenchymal transition and autophagy: a conflicting triangle. Cancer Lett. 585, 216661 (2024).","journal-title":"Cancer Lett."},{"key":"2924_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01515-8","volume":"17","author":"C Cao","year":"2025","unstructured":"Cao, C. et al. Blocking CXCR4(+) CD4(+) T cells reprograms T(reg)-mediated immunosuppression via modulating the Rho-GTPase\/NF-kappaB signaling axis. Genome Med. 17, 85 (2025).","journal-title":"Genome Med."},{"key":"2924_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100659","volume":"4","author":"C Cao","year":"2024","unstructured":"Cao, C. et al. CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8(+) T cells via JAK2\/STAT3 pathway. Cell Genom. 4, 100659 (2024).","journal-title":"Cell Genom."},{"key":"2924_CR89","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","volume":"42","author":"HN Bell","year":"2024","unstructured":"Bell, H. N. & Zou, W. Beyond the barrier: unraveling the mechanisms of immunotherapy resistance. Annu Rev. Immunol. 42, 521\u2013550 (2024).","journal-title":"Annu Rev. Immunol."},{"key":"2924_CR90","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea, M. et al. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 11, 874\u2013899 (2021).","journal-title":"Cancer Discov."},{"key":"2924_CR91","first-page":"27","volume":"8","author":"NM Stubbs","year":"2025","unstructured":"Stubbs, N. M. et al. Acquired resistance to molecularly targeted therapies for cancer. Cancer Drug Resist. 8, 27 (2025).","journal-title":"Cancer Drug Resist."},{"key":"2924_CR92","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jtho.2024.06.004","volume":"19","author":"K Pan","year":"2024","unstructured":"Pan, K. et al. Mutational characteristics and clinical outcomes for lung adenocarcinoma with EGFR germline mutations. J. Thorac. Oncol. 19, 1438\u20131448 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"2924_CR93","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.cllc.2023.07.003","volume":"24","author":"A Russo","year":"2023","unstructured":"Russo, A. et al. Tracking clonal evolution of EGFR-mutated non-small cell lung cancer through liquid biopsy: management of C797S acquired mutation. Clin. Lung Cancer 24, 660\u2013665 (2023).","journal-title":"Clin. Lung Cancer"},{"key":"2924_CR94","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1002\/mco2.694","volume":"5","author":"X Ou","year":"2024","unstructured":"Ou, X., Gao, G., Habaz, I. A. & Wang, Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm. 5, e694 (2024).","journal-title":"MedComm."},{"key":"2924_CR95","doi-asserted-by":"publisher","first-page":"107826","DOI":"10.1016\/j.compbiomed.2023.107826","volume":"169","author":"HJG Lindstrom","year":"2024","unstructured":"Lindstrom, H. J. G., de Wijn, A. S. & Friedman, R. Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: understanding and implications studied with stochastic models. Comput. Biol. Med. 169, 107826 (2024).","journal-title":"Comput. Biol. Med."},{"key":"2924_CR96","doi-asserted-by":"crossref","unstructured":"Nakazawa, S. et al. Activating mutations in the MET kinase domain co-occur with other driver oncogenes and mediate resistance to targeted therapy in NSCLC. J. Thorac. Oncol. 20, 1035\u20131049 (2025).","DOI":"10.1016\/j.jtho.2025.03.045"},{"key":"2924_CR97","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-018-0022-x","volume":"24","author":"GS Wong","year":"2018","unstructured":"Wong, G. S. et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat. Med. 24, 968\u2013977 (2018).","journal-title":"Nat. Med."},{"key":"2924_CR98","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.18.00177","volume":"37","author":"GGY Lai","year":"2019","unstructured":"Lai, G. G. Y. et al. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer. J. Clin. Oncol. 37, 876\u2013884 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2924_CR99","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s10495-024-01967-0","volume":"29","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K\/AKT\/p53 signaling axis. Apoptosis 29, 1161\u20131184 (2024).","journal-title":"Apoptosis"},{"key":"2924_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101042","volume":"73","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Inhibition of NF-kappaB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resist. Updat. 73, 101042 (2024).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07772-0","volume":"16","author":"S Ye","year":"2025","unstructured":"Ye, S. et al. Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis. Cell Death Dis. 16, 448 (2025).","journal-title":"Cell Death Dis."},{"key":"2924_CR102","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ncb3626","volume":"19","author":"B Rondinelli","year":"2017","unstructured":"Rondinelli, B. et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat. Cell Biol. 19, 1371\u20131378 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2924_CR103","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/j.molcel.2025.06.004","volume":"85","author":"S Zhu","year":"2025","unstructured":"Zhu, S. et al. Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer. Mol. Cell 85, 2673\u20132687.e2678 (2025).","journal-title":"Mol. Cell"},{"key":"2924_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104407","volume":"30","author":"SK Roberts","year":"2025","unstructured":"Roberts, S. K. et al. Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance. Drug Discov. Today 30, 104407 (2025).","journal-title":"Drug Discov. Today"},{"key":"2924_CR105","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-025-00928-z","volume":"6","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer. Nat. Cancer 6, 629\u2013646 (2025).","journal-title":"Nat. Cancer"},{"key":"2924_CR106","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.ccell.2025.04.002","volume":"43","author":"J Guo","year":"2025","unstructured":"Guo, J. et al. KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy. Cancer Cell 43, 1261\u20131278.e1210 (2025).","journal-title":"Cancer Cell"},{"key":"2924_CR107","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","volume":"42","author":"X Tong","year":"2024","unstructured":"Tong, X. et al. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell 42, 413\u2013428.e417 (2024).","journal-title":"Cancer Cell"},{"key":"2924_CR108","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/bjc.2016.203","volume":"115","author":"A Vaidyanathan","year":"2016","unstructured":"Vaidyanathan, A. et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br. J. Cancer 115, 431\u2013441 (2016).","journal-title":"Br. J. Cancer"},{"key":"2924_CR109","doi-asserted-by":"crossref","unstructured":"Pan, D. et al. BRD4 regulates PAI-1 expression in tumor-associated macrophages to drive chemoresistance in colorectal cancer. Oncogene 44, 2778\u20132791 (2025).","DOI":"10.1038\/s41388-025-03453-6"},{"key":"2924_CR110","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771\u2013784 (2011).","journal-title":"Lancet"},{"key":"2924_CR111","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/ijms14010108","volume":"14","author":"R Garcia-Becerra","year":"2012","unstructured":"Garcia-Becerra, R., Santos, N., Diaz, L. & Camacho, J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J. Mol. Sci. 14, 108\u2013145 (2012).","journal-title":"Int J. Mol. Sci."},{"key":"2924_CR112","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1210\/me.2001-0347","volume":"16","author":"M Stoner","year":"2002","unstructured":"Stoner, M. et al. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol. Endocrinol. 16, 2231\u20132242 (2002).","journal-title":"Mol. Endocrinol."},{"key":"2924_CR113","doi-asserted-by":"crossref","unstructured":"Raheem, F. et al. Metastatic ER+ breast cancer: mechanisms of resistance and future therapeutic approaches. Int. J. Mol. Sci. 24, 16198 (2023).","DOI":"10.3390\/ijms242216198"},{"key":"2924_CR114","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/0008-5472.CAN-20-4037","volume":"81","author":"F Hermida-Prado","year":"2021","unstructured":"Hermida-Prado, F. & Jeselsohn, R. The ESR1 mutations: from bedside to bench to bedside. Cancer Res. 81, 537\u2013538 (2021).","journal-title":"Cancer Res."},{"key":"2924_CR115","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fonc.2017.00026","volume":"7","author":"T Reinert","year":"2017","unstructured":"Reinert, T., Saad, E. D., Barrios, C. H. & Bines, J. Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer. Front. Oncol. 7, 26 (2017).","journal-title":"Front. Oncol."},{"key":"2924_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00523-4","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel, R., Klein, P., Tiersten, A. & Sparano, J. A. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. npj Breast Cancer 9, 20 (2023).","journal-title":"npj Breast Cancer"},{"key":"2924_CR117","doi-asserted-by":"publisher","first-page":"101430","DOI":"10.1016\/j.gendis.2024.101430","volume":"12","author":"Y Wang","year":"2025","unstructured":"Wang, Y., Rozen, V., Zhao, Y. & Wang, Z. Oncogenic activation of PI K3 CA in cancers: Emerging targeted therapies in precision oncology. Genes Dis. 12, 101430 (2025).","journal-title":"Genes Dis."},{"key":"2924_CR118","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34, 427\u2013438.e426 (2018).","journal-title":"Cancer Cell"},{"key":"2924_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403592","volume":"11","author":"KM Zhang","year":"2024","unstructured":"Zhang, K. M. et al. Inactivated cGAS-STING signaling facilitates endocrine resistance by forming a positive feedback loop with AKT kinase in ER+HER2- breast cancer. Adv. Sci. 11, e2403592 (2024).","journal-title":"Adv. Sci."},{"key":"2924_CR120","doi-asserted-by":"crossref","unstructured":"Sobhani, N. et al. AR-V7 in metastatic prostate cancer: a strategy beyond redemption. Int. J. Mol. Sci. 22, 5515 (2021).","DOI":"10.3390\/ijms22115515"},{"key":"2924_CR121","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg4132","volume":"14","author":"M Sawant","year":"2022","unstructured":"Sawant, M. et al. Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. Sci. Transl. Med. 14, eabg4132 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2924_CR122","first-page":"568","volume":"20","author":"B Cheng","year":"2023","unstructured":"Cheng, B. & Huang, H. Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment. Cancer Biol. Med. 20, 568\u2013574 (2023).","journal-title":"Cancer Biol. Med."},{"key":"2924_CR123","doi-asserted-by":"crossref","unstructured":"Kilmister, E. J. et al. Cancer metastasis and treatment resistance: mechanistic insights and therapeutic targeting of cancer stem cells and the tumor microenvironment. Biomedicines. 10, 2988 (2022).","DOI":"10.3390\/biomedicines10112988"},{"key":"2924_CR124","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/emph\/eow015","volume":"2016","author":"CM Worsley","year":"2016","unstructured":"Worsley, C. M., Mayne, E. S. & Veale, R. B. Clone wars: the evolution of therapeutic resistance in cancer. Evol. Med. Public Health 2016, 180\u2013181 (2016).","journal-title":"Evol. Med. Public Health"},{"key":"2924_CR125","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2924_CR126","doi-asserted-by":"publisher","first-page":"217792","DOI":"10.1016\/j.canlet.2025.217792","volume":"626","author":"Z Jin","year":"2025","unstructured":"Jin, Z., Zhang, C., Shen, L. & Cao, Y. Harnessing exosomes: from tumor immune escape to therapeutic innovation in gastric cancer immunotherapy. Cancer Lett. 626, 217792 (2025).","journal-title":"Cancer Lett."},{"key":"2924_CR127","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie, Y., Tang, F., Wei, Y. Q. & Wei, X. W. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J. Hematol. Oncol. 15, 61 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2924_CR128","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00262-020-02842-y","volume":"70","author":"V Sasidharan Nair","year":"2021","unstructured":"Sasidharan Nair, V. et al. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. Cancer Immunol. Immunother. 70, 2103\u20132121 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"2924_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02363-1","volume":"24","author":"X Wu","year":"2025","unstructured":"Wu, X., Que, H., Li, Q. & Wei, X. Wnt\/beta-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy. Mol. Cancer 24, 171 (2025).","journal-title":"Mol. Cancer"},{"key":"2924_CR130","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","volume":"16","author":"A De Luca","year":"2012","unstructured":"De Luca, A. et al. The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets 16, S17\u2013S27 (2012).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2924_CR131","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin, H., Wang, L. & Bernards, R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat. Rev. Drug Discov. 22, 213\u2013234 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2924_CR132","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A Perez-Gonzalez","year":"2023","unstructured":"Perez-Gonzalez, A., Bevant, K. & Blanpain, C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat. Cancer 4, 1063\u20131082 (2023).","journal-title":"Nat. Cancer"},{"key":"2924_CR133","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s43018-024-00794-1","volume":"5","author":"BM Robertson","year":"2024","unstructured":"Robertson, B. M., Fane, M. E., Weeraratna, A. T. & Rebecca, V. W. Determinants of resistance and response to melanoma therapy. Nat. Cancer 5, 964\u2013982 (2024).","journal-title":"Nat. Cancer"},{"key":"2924_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06306-8","volume":"23","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Mechanical forces in the tumor microenvironment: roles, pathways, and therapeutic approaches. J. Transl. Med. 23, 313 (2025).","journal-title":"J. Transl. Med."},{"key":"2924_CR135","doi-asserted-by":"crossref","unstructured":"Fu, Y. et al. Decoding the CAF-TAM axis: multi-omics dissection and therapeutic targeting of stromal-immune crosstalk in the tumor microenvironment. Cell Death Dis. 17, 515 (2026).","DOI":"10.1038\/s41419-026-08685-2"},{"key":"2924_CR136","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2023.03.008","volume":"41","author":"A Mousset","year":"2023","unstructured":"Mousset, A. et al. Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-beta activation. Cancer Cell 41, 757\u2013775.e710 (2023).","journal-title":"Cancer Cell"},{"key":"2924_CR137","doi-asserted-by":"crossref","unstructured":"Jeong, H. et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer. J. Immunother. Cancer. 13, e010612 (2025).","DOI":"10.1136\/jitc-2024-010612"},{"key":"2924_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113520","volume":"153","author":"CF Chiu","year":"2022","unstructured":"Chiu, C. F. et al. Organic cation transporter 2 activation enhances sensitivity to oxaliplatin in human pancreatic ductal adenocarcinoma. Biomed. Pharmacother. 153, 113520 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"2924_CR139","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1476-5381.2009.00569.x","volume":"159","author":"H Burger","year":"2010","unstructured":"Burger, H. et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br. J. Pharm. 159, 898\u2013908 (2010).","journal-title":"Br. J. Pharm."},{"key":"2924_CR140","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrd4626","volume":"14","author":"L Lin","year":"2015","unstructured":"Lin, L., Yee, S. W., Kim, R. B. & Giacomini, K. M. SLC transporters as therapeutic targets: emerging opportunities. Nat. Rev. Drug Discov. 14, 543\u2013560 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2924_CR141","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1039\/C6MD00005C","volume":"7","author":"C Colas","year":"2016","unstructured":"Colas, C., Ung, P. M. & Schlessinger, A. SLC transporters: structure, function, and drug discovery. Medchemcomm 7, 1069\u20131081 (2016).","journal-title":"Medchemcomm"},{"key":"2924_CR142","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cmet.2024.11.012","volume":"37","author":"Y Fan","year":"2025","unstructured":"Fan, Y. et al. Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1. Cell Metab. 37, 514\u2013526.e515 (2025).","journal-title":"Cell Metab."},{"key":"2924_CR143","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrm2646","volume":"10","author":"DC Rees","year":"2009","unstructured":"Rees, D. C., Johnson, E. & Lewinson, O. ABC transporters: the power to change. Nat. Rev. Mol. Cell Biol. 10, 218\u2013227 (2009).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2924_CR144","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452\u2013464 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2924_CR145","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1039\/D3MD00612C","volume":"15","author":"F Cao","year":"2024","unstructured":"Cao, F. et al. Synthesis and evaluation of WK-X-34 derivatives as P-glycoprotein (P-gp\/ABCB1) inhibitors for reversing multidrug resistance. RSC Med. Chem. 15, 506\u2013518 (2024).","journal-title":"RSC Med. Chem."},{"key":"2924_CR146","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","volume":"201","author":"D Keppler","year":"2011","unstructured":"Keppler, D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp. Pharmacol 201, 299\u2013323 (2011).","journal-title":"Handb Exp. Pharmacol"},{"key":"2924_CR147","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","volume":"17","author":"Q Mao","year":"2015","unstructured":"Mao, Q. & Unadkat, J. D. Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2013an update. AAPS J. 17, 65\u201382 (2015).","journal-title":"AAPS J."},{"key":"2924_CR148","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","volume":"21","author":"LM Hodges","year":"2011","unstructured":"Hodges, L. M. et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet. Genom. 21, 152\u2013161 (2011).","journal-title":"Pharmacogenet. Genom."},{"key":"2924_CR149","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1016\/j.apsb.2022.03.023","volume":"12","author":"S-Q Wang","year":"2022","unstructured":"Wang, S.-Q. et al. Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. Acta Pharm. Sin. B 12, 3263\u20133280 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"2924_CR150","first-page":"545","volume":"40","author":"I Sugawara","year":"1990","unstructured":"Sugawara, I. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathol. Jpn. 40, 545\u2013553 (1990).","journal-title":"Acta Pathol. Jpn."},{"key":"2924_CR151","doi-asserted-by":"publisher","first-page":"104161","DOI":"10.1016\/j.drudis.2024.104161","volume":"29","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators. Drug Discov. Today 29, 104161 (2024).","journal-title":"Drug Discov. Today"},{"key":"2924_CR152","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/sj.bjc.6605590","volume":"102","author":"N Walsh","year":"2010","unstructured":"Walsh, N. et al. Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. Br. J. Cancer 102, 1157\u20131162 (2010).","journal-title":"Br. J. Cancer"},{"key":"2924_CR153","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abn2707","volume":"15","author":"AM Kurimchak","year":"2022","unstructured":"Kurimchak, A. M. et al. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Sci. Signal 15, eabn2707 (2022).","journal-title":"Sci. Signal"},{"key":"2924_CR154","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.drup.2021.100743","volume":"54","author":"JQ Wang","year":"2021","unstructured":"Wang, J. Q. et al. Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance. Drug Resist. Updat. 54, 100743 (2021).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR155","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cell.2017.12.005","volume":"172","author":"ZL Johnson","year":"2018","unstructured":"Johnson, Z. L. & Chen, J. ATP binding enables substrate release from multidrug resistance protein 1. Cell 172, 81\u201389.e10 (2018).","journal-title":"Cell"},{"key":"2924_CR156","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1208\/s12248-015-9757-1","volume":"17","author":"YK Zhang","year":"2015","unstructured":"Zhang, Y. K., Wang, Y. J., Gupta, P. & Chen, Z. S. Multidrug resistance proteins (MRPs) and cancer therapy. AAPS J. 17, 802\u2013812 (2015).","journal-title":"AAPS J."},{"key":"2924_CR157","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5732\/cjc.011.10329","volume":"31","author":"K Sodani","year":"2012","unstructured":"Sodani, K., Patel, A., Kathawala, R. J. & Chen, Z. S. Multidrug resistance associated proteins in multidrug resistance. Chin. J. Cancer 31, 58\u201372 (2012).","journal-title":"Chin. J. Cancer"},{"key":"2924_CR158","doi-asserted-by":"publisher","first-page":"100795","DOI":"10.1016\/j.drup.2021.100795","volume":"59","author":"KM Hanssen","year":"2021","unstructured":"Hanssen, K. M., Haber, M. & Fletcher, J. I. Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: beyond pharmacological inhibition. Drug Resist. Updat. 59, 100795 (2021).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR159","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.xphs.2018.10.043","volume":"108","author":"K Sawangrat","year":"2019","unstructured":"Sawangrat, K. et al. Modulation of intestinal transport and absorption of topotecan, a BCRP substrate, by various pharmaceutical excipients and their inhibitory mechanisms of BCRP transporter. J. Pharm. Sci. 108, 1315\u20131325 (2019).","journal-title":"J. Pharm. Sci."},{"key":"2924_CR160","doi-asserted-by":"publisher","first-page":"123245","DOI":"10.1016\/j.lfs.2024.123245","volume":"360","author":"NE El-Ashmawy","year":"2025","unstructured":"El-Ashmawy, N. E., Al-Ashmawy, G. M., Hamada, O. B. & Khedr, N. F. The role of ABCG2 in health and disease: Linking cancer therapy resistance and other disorders. Life Sci. 360, 123245 (2025).","journal-title":"Life Sci."},{"key":"2924_CR161","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abp9530","volume":"9","author":"R Uceda-Castro","year":"2023","unstructured":"Uceda-Castro, R. et al. BCRP drives intrinsic chemoresistance in chemotherapy-naive breast cancer brain metastasis. Sci. Adv. 9, eabp9530 (2023).","journal-title":"Sci. Adv."},{"key":"2924_CR162","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4077\/CJP.2016.BAF426","volume":"59","author":"YL Chen","year":"2016","unstructured":"Chen, Y. L. et al. Mechanisms underlying lung resistance-related protein (LRP)-mediated doxorubicin resistance of non-small cell lung cancer cells. Chin. J. Physiol. 59, 331\u2013347 (2016).","journal-title":"Chin. J. Physiol."},{"key":"2924_CR163","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1631\/jzus.B1700129","volume":"18","author":"LN Pan","year":"2017","unstructured":"Pan, L. N., Zhang, Y., Zhu, C. J. & Dong, Z. X. Kinesin KIF4A is associated with chemotherapeutic drug resistance by regulating intracellular trafficking of lung resistance-related protein. J. Zhejiang Univ. Sci. B 18, 1046\u20131054 (2017).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"2924_CR164","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1124\/dmd.122.001131","volume":"51","author":"F Wang","year":"2023","unstructured":"Wang, F. et al. Activation\/inactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy. Drug Metab. Dispos. 51, 543\u2013559 (2023).","journal-title":"Drug Metab. Dispos."},{"key":"2924_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40579-1","volume":"14","author":"Q Cai","year":"2023","unstructured":"Cai, Q. et al. Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment. Nat. Commun. 14, 4934 (2023).","journal-title":"Nat. Commun."},{"key":"2924_CR166","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1021\/acsmedchemlett.0c00202","volume":"11","author":"J Shanu-Wilson","year":"2020","unstructured":"Shanu-Wilson, J. et al. Biotransformation: impact and application of metabolism in drug discovery. ACS Med Chem. Lett. 11, 2087\u20132107 (2020).","journal-title":"ACS Med Chem. Lett."},{"key":"2924_CR167","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1124\/dmd.118.083766","volume":"47","author":"DA Ramirez","year":"2019","unstructured":"Ramirez, D. A. et al. Kinetics of cyclophosphamide metabolism in humans, dogs, cats, and mice and relationship to cytotoxic activity and pharmacokinetics. Drug Metab. Dispos. 47, 257\u2013268 (2019).","journal-title":"Drug Metab. Dispos."},{"key":"2924_CR168","first-page":"6","volume":"5","author":"RSK Nagampalli","year":"2025","unstructured":"Nagampalli, R. S. K., Vadla, G. P. & Nadendla, E. K. Emerging strategies to overcome chemoresistance: structural insights and therapeutic targeting of multidrug resistance-linked ATP-binding cassette transporters. Int J. Transl. Med. 5, 6 (2025).","journal-title":"Int J. Transl. Med."},{"key":"2924_CR169","doi-asserted-by":"publisher","first-page":"108488","DOI":"10.1016\/j.pharmthera.2023.108488","volume":"249","author":"J Dong","year":"2023","unstructured":"Dong, J. et al. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review. Pharm. Ther. 249, 108488 (2023).","journal-title":"Pharm. Ther."},{"key":"2924_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01626-z","volume":"20","author":"P Yadav","year":"2022","unstructured":"Yadav, P., Ambudkar, S. V. & Prasad, N. R. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer. J. Nanobiotechnol. 20, 423 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"2924_CR171","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1021\/acs.jmedchem.7b01457","volume":"61","author":"D Waghray","year":"2018","unstructured":"Waghray, D. & Zhang, Q. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J. Med Chem. 61, 5108\u20135121 (2018).","journal-title":"J. Med Chem."},{"key":"2924_CR172","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105274","volume":"9","author":"Q Xiao","year":"2022","unstructured":"Xiao, Q. et al. Lemon-derived extracellular vesicles nanodrugs enable to efficiently overcome cancer multidrug resistance by endocytosis-triggered energy dissipation and energy production reduction. Adv. Sci. 9, e2105274 (2022).","journal-title":"Adv. Sci."},{"key":"2924_CR173","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejmech.2019.05.027","volume":"176","author":"A Kumar","year":"2019","unstructured":"Kumar, A. & Jaitak, V. Natural products as multidrug resistance modulators in cancer. Eur. J. Med. Chem. 176, 268\u2013291 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"2924_CR174","doi-asserted-by":"publisher","first-page":"18764","DOI":"10.1021\/acs.jmedchem.4c01081","volume":"67","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Cell-based screen identifies a highly potent and orally available ABCB1 modulator for treatment of multidrug resistance. J. Med Chem. 67, 18764\u201318780 (2024).","journal-title":"J. Med Chem."},{"key":"2924_CR175","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.bcp.2009.10.017","volume":"79","author":"Z Liang","year":"2010","unstructured":"Liang, Z. et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharm. 79, 817\u2013824 (2010).","journal-title":"Biochem. Pharm."},{"key":"2924_CR176","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ncrna.2021.12.001","volume":"6","author":"P Mondal","year":"2021","unstructured":"Mondal, P. & Meeran, S. M. microRNAs in cancer chemoresistance: the sword and the shield. Noncoding RNA Res. 6, 200\u2013210 (2021).","journal-title":"Noncoding RNA Res."},{"key":"2924_CR177","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41586-018-0083-5","volume":"557","author":"H Ho","year":"2018","unstructured":"Ho, H. et al. Structural basis for dual-mode inhibition of the ABC transporter MsbA. Nature 557, 196\u2013201 (2018).","journal-title":"Nature"},{"key":"2924_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101208","volume":"79","author":"M Sun","year":"2025","unstructured":"Sun, M. et al. Rational design of peptides to overcome drug resistance by metabolic regulation. Drug Resist. Updat. 79, 101208 (2025).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR179","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3892\/ijo.2015.3256","volume":"48","author":"Y Sun","year":"2016","unstructured":"Sun, Y. et al. NF-kappaB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression. Int J. Oncol. 48, 225\u2013234 (2016).","journal-title":"Int J. Oncol."},{"key":"2924_CR180","first-page":"763","volume":"42","author":"R Vaclavikova","year":"2019","unstructured":"Vaclavikova, R. et al. Development of high\u2011resolution melting analysis for ABCB1 promoter methylation: clinical consequences in breast and ovarian carcinoma. Oncol. Rep. 42, 763\u2013774 (2019).","journal-title":"Oncol. Rep."},{"key":"2924_CR181","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.trecan.2023.07.006","volume":"9","author":"M Kalli","year":"2023","unstructured":"Kalli, M., Poskus, M. D., Stylianopoulos, T. & Zervantonakis, I. K. Beyond matrix stiffness: targeting force-induced cancer drug resistance. Trends Cancer 9, 937\u2013954 (2023).","journal-title":"Trends Cancer"},{"key":"2924_CR182","doi-asserted-by":"publisher","first-page":"10349","DOI":"10.1039\/D2SC02708A","volume":"13","author":"S Kuermanbayi","year":"2022","unstructured":"Kuermanbayi, S. et al. In situ monitoring of functional activity of extracellular matrix stiffness-dependent multidrug resistance protein 1 using scanning electrochemical microscopy. Chem. Sci. 13, 10349\u201310360 (2022).","journal-title":"Chem. Sci."},{"key":"2924_CR183","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2023","unstructured":"Lei, Z. N. et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 4, e265 (2023).","journal-title":"MedComm."},{"key":"2924_CR184","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11538-021-00935-y","volume":"83","author":"S Hamis","year":"2021","unstructured":"Hamis, S., Yates, J., Chaplain, M. A. J. & Powathil, G. G. Targeting cellular DNA damage responses in cancer: an in vitro-calibrated agent-based model simulating monolayer and spheroid treatment responses to ATR-inhibiting drugs. Bull. Math. Biol. 83, 103 (2021).","journal-title":"Bull. Math. Biol."},{"key":"2924_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115047","volume":"43","author":"Q Pan","year":"2024","unstructured":"Pan, Q. et al. Mapping functional elements of the DNA damage response through base editor screens. Cell Rep. 43, 115047 (2024).","journal-title":"Cell Rep."},{"key":"2924_CR186","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.molcel.2023.12.001","volume":"84","author":"E Georgiades","year":"2024","unstructured":"Georgiades, E., Crosetto, N. & Bienko, M. Compartmentalizing damaged DNA: a double-edged sword. Mol. Cell 84, 12\u201313 (2024).","journal-title":"Mol. Cell"},{"key":"2924_CR187","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/cac2.12358","volume":"42","author":"R Hong","year":"2022","unstructured":"Hong, R. & Xu, B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun. (Lond.) 42, 913\u2013936 (2022).","journal-title":"Cancer Commun. (Lond.)"},{"key":"2924_CR188","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"2924_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06984-0","volume":"15","author":"M Xiao","year":"2024","unstructured":"Xiao, M. et al. NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy. Cell Death Dis. 15, 620 (2024).","journal-title":"Cell Death Dis."},{"key":"2924_CR190","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn1229","volume":"8","author":"M Stanzione","year":"2022","unstructured":"Stanzione, M. et al. Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. Sci. Adv. 8, eabn1229 (2022).","journal-title":"Sci. Adv."},{"key":"2924_CR191","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly, F. J. et al. Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer 23, 78\u201394 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2924_CR192","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-19-3373","volume":"26","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Wee1 kinase inhibitor AZD1775 effectively sensitizes esophageal cancer to radiotherapy. Clin. Cancer Res. 26, 3740\u20133750 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2924_CR193","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner, A. M. et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models. Mol. Cancer Ther. 19, 26\u201338 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2924_CR194","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","volume":"619","author":"AVR Kornepati","year":"2023","unstructured":"Kornepati, A. V. R., Rogers, C. M., Sung, P. & Curiel, T. J. The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature 619, 475\u2013486 (2023).","journal-title":"Nature"},{"key":"2924_CR195","doi-asserted-by":"crossref","unstructured":"Zhang, R. et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc. Natl. Acad Sci USA. 119, e2114851119 (2022).","DOI":"10.1073\/pnas.2114851119"},{"key":"2924_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46283-y","volume":"15","author":"Z Ye","year":"2024","unstructured":"Ye, Z. et al. GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer. Nat. Commun. 15, 2132 (2024).","journal-title":"Nat. Commun."},{"key":"2924_CR197","first-page":"984","volume":"4","author":"M Estruch","year":"2021","unstructured":"Estruch, M. et al. Targeting of PI3K\/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance. Cancer Drug Resist, 4, 984\u2013995 (2021).","journal-title":"Cancer Drug Resist,"},{"key":"2924_CR198","doi-asserted-by":"publisher","first-page":"703","DOI":"10.20517\/cdr.2022.36","volume":"5","author":"E Vickridge","year":"2022","unstructured":"Vickridge, E., Faraco, C. C. F. & Nepveu, A. Base excision repair accessory factors in senescence avoidance and resistance to treatments. Cancer Drug Resist. 5, 703\u2013720 (2022).","journal-title":"Cancer Drug Resist."},{"key":"2924_CR199","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817 (2017).","journal-title":"Mol. Cell"},{"key":"2924_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03720-0","volume":"20","author":"X Du","year":"2022","unstructured":"Du, X. et al. Irradiation-induced exosomal HMGB1 to confer radioresistance via the PI3K\/AKT\/FOXO3A signaling pathway in ESCC. J. Transl. Med. 20, 507 (2022).","journal-title":"J. Transl. Med."},{"key":"2924_CR201","doi-asserted-by":"crossref","unstructured":"Kciuk, M. et al. PD-1\/PD-L1 and DNA damage response in cancer. Cells. 12, 530 (2023).","DOI":"10.3390\/cells12040530"},{"key":"2924_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112768","volume":"140","author":"M He","year":"2024","unstructured":"He, M. et al. The crosstalk between DNA-damage responses and innate immunity. Int Immunopharmacol. 140, 112768 (2024).","journal-title":"Int Immunopharmacol."},{"key":"2924_CR203","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.7150\/thno.39341","volume":"10","author":"Z Wu","year":"2020","unstructured":"Wu, Z. et al. Copy number amplification of DNA damage repair pathways potentiates therapeutic resistance in cancer. Theranostics 10, 3939\u20133951 (2020).","journal-title":"Theranostics"},{"key":"2924_CR204","doi-asserted-by":"crossref","unstructured":"Zhu, K. et al. PI3K\/AKT\/mTOR-targeted therapy for breast cancer. Cells. 11, 2508 (2022).","DOI":"10.3390\/cells11162508"},{"key":"2924_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A. et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).","journal-title":"Mol. Cancer"},{"key":"2924_CR206","doi-asserted-by":"crossref","unstructured":"Ahmad, I. et al. Curcumin and plumbagin synergistically target the PI3K\/Akt\/mTOR pathway: a prospective role in cancer treatment. Int. J. Mol. Sci. 24, 6651 (2023).","DOI":"10.3390\/ijms24076651"},{"key":"2924_CR207","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 518, 240\u2013244 (2015).","journal-title":"Nature"},{"key":"2924_CR208","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne, I. M. et al. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 25, e139\u2013e151 (2024).","journal-title":"Lancet Oncol."},{"key":"2924_CR209","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1038\/onc.2015.414","volume":"35","author":"A Alayev","year":"2016","unstructured":"Alayev, A. et al. mTORC1 directly phosphorylates and activates ERalpha upon estrogen stimulation. Oncogene 35, 3535\u20133543 (2016).","journal-title":"Oncogene"},{"key":"2924_CR210","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943\u20131947 (1997).","journal-title":"Science"},{"key":"2924_CR211","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01284-9","volume":"22","author":"O Martinez-Saez","year":"2020","unstructured":"Martinez-Saez, O. et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 22, 45 (2020).","journal-title":"Breast Cancer Res."},{"key":"2924_CR212","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1038\/onc.2009.516","volume":"29","author":"J Lauring","year":"2010","unstructured":"Lauring, J. et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 29, 2337\u20132345 (2010).","journal-title":"Oncogene"},{"key":"2924_CR213","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-18-0430","volume":"78","author":"A Ruiz-Saenz","year":"2018","unstructured":"Ruiz-Saenz, A. et al. HER2 amplification in tumors activates PI3K\/Akt signaling independent of HER3. Cancer Res. 78, 3645\u20133658 (2018).","journal-title":"Cancer Res."},{"key":"2924_CR214","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/JCI41680","volume":"120","author":"TW Miller","year":"2010","unstructured":"Miller, T. W. et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Investig. 120, 2406\u20132413 (2010).","journal-title":"J. Clin. Investig."},{"key":"2924_CR215","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/cas.14230","volume":"111","author":"D Li","year":"2020","unstructured":"Li, D. et al. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K\/Akt\/mTOR in breast cancer. Cancer Sci. 111, 47\u201358 (2020).","journal-title":"Cancer Sci."},{"key":"2924_CR216","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang, W. & Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12, 9\u201318 (2002).","journal-title":"Cell Res."},{"key":"2924_CR217","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nri3495","volume":"13","author":"JS Arthur","year":"2013","unstructured":"Arthur, J. S. & Ley, S. C. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 13, 679\u2013692 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"2924_CR218","doi-asserted-by":"publisher","first-page":"104497","DOI":"10.1016\/j.critrevonc.2024.104497","volume":"204","author":"M Liu","year":"2024","unstructured":"Liu, M. et al. Colorectal cancer with BRAF V600E mutation: trends in immune checkpoint inhibitor treatment. Crit. Rev. Oncol. Hematol. 204, 104497 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2924_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114290","volume":"210","author":"M Ambrosini","year":"2024","unstructured":"Ambrosini, M. et al. BRAF + EGFR +\/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Eur. J. Cancer 210, 114290 (2024).","journal-title":"Eur. J. Cancer"},{"key":"2924_CR220","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s12276-025-01544-8","volume":"57","author":"CS Bunardi","year":"2025","unstructured":"Bunardi, C. S. et al. MAP4K signaling pathways in cancer: roles, mechanisms and therapeutic opportunities. Exp. Mol. Med. 57, 2148\u20132156 (2025).","journal-title":"Exp. Mol. Med."},{"key":"2924_CR221","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","volume":"21","author":"AJ Hanrahan","year":"2024","unstructured":"Hanrahan, A. J., Chen, Z., Rosen, N. & Solit, D. B. BRAF - a tumour-agnostic drug target with lineage-specific dependencies. Nat. Rev. Clin. Oncol. 21, 224\u2013247 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2924_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59588-3","volume":"16","author":"X Qu","year":"2025","unstructured":"Qu, X. et al. Ligand-activated EGFR\/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer. Nat. Commun. 16, 4332 (2025).","journal-title":"Nat. Commun."},{"key":"2924_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101002","volume":"4","author":"P Auf der Maur","year":"2023","unstructured":"Auf der Maur, P. et al. N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kalpha inhibition in breast cancer. Cell Rep. Med. 4, 101002 (2023).","journal-title":"Cell Rep. Med."},{"key":"2924_CR224","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01358-y","volume":"20","author":"T Jiang","year":"2021","unstructured":"Jiang, T. et al. A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling. Mol. Cancer 20, 66 (2021).","journal-title":"Mol. Cancer"},{"key":"2924_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215598","volume":"532","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. PMN-MDSCs accumulation induced by CXCL1 promotes CD8(+) T cells exhaustion in gastric cancer. Cancer Lett. 532, 215598 (2022).","journal-title":"Cancer Lett."},{"key":"2924_CR226","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s44466-025-00014-0","volume":"1","author":"A Hoffmann","year":"2025","unstructured":"Hoffmann, A., Cheng, G. & Baltimore, D. NF-kappaB: master regulator of cellular responses in health and disease. Immun. Inflamm. 1, 2 (2025).","journal-title":"Immun. Inflamm."},{"key":"2924_CR227","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm2083","volume":"8","author":"ND Perkins","year":"2007","unstructured":"Perkins, N. D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8, 49\u201362 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2924_CR228","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun, S. C. Non-canonical NF-kappaB signaling pathway. Cell Res. 21, 71\u201385 (2011).","journal-title":"Cell Res."},{"key":"2924_CR229","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20664-5","volume":"12","author":"S Kumar","year":"2021","unstructured":"Kumar, S. et al. Dll1(+) quiescent tumor stem cells drive chemoresistance in breast cancer through NF-kappaB survival pathway. Nat. Commun. 12, 432 (2021).","journal-title":"Nat. Commun."},{"key":"2924_CR230","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1038\/s41388-018-0562-z","volume":"38","author":"S Kumar","year":"2019","unstructured":"Kumar, S. et al. Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer. Oncogene 38, 2092\u20132107 (2019).","journal-title":"Oncogene"},{"key":"2924_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05972-0","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang, Y. et al. HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-kappaB signaling pathway in breast cancer. Cell Death Dis. 14, 434 (2023).","journal-title":"Cell Death Dis."},{"key":"2924_CR232","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-018-0621-5","volume":"11","author":"S Balaji","year":"2018","unstructured":"Balaji, S. et al. NF-kappaB signaling and its relevance to the treatment of mantle cell lymphoma. J. Hematol. Oncol. 11, 83 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2924_CR233","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-022-02243-2","volume":"41","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. J. Exp. Clin. Cancer Res. 41, 66 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2924_CR234","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","volume":"55","author":"L Cucolo","year":"2022","unstructured":"Cucolo, L. et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity 55, 671\u2013685.e610 (2022).","journal-title":"Immunity"},{"key":"2924_CR235","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak, S. & Ten Dijke, P. Targeting TGF-beta signaling in cancer. Trends Cancer 3, 56\u201371 (2017).","journal-title":"Trends Cancer"},{"key":"2924_CR236","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41401-024-01235-6","volume":"45","author":"ZJ Chia","year":"2024","unstructured":"Chia, Z. J., Cao, Y. N., Little, P. J. & Kamato, D. Transforming growth factor-beta receptors: versatile mechanisms of ligand activation. Acta Pharm. Sin. 45, 1337\u20131348 (2024).","journal-title":"Acta Pharm. Sin."},{"key":"2924_CR237","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402327","volume":"11","author":"K Liu","year":"2024","unstructured":"Liu, K. et al. Stabilization of TGF-beta receptor 1 by a receptor-associated adaptor dictates feedback activation of the TGF-beta signaling pathway to maintain liver cancer stemness and drug resistance. Adv. Sci. 11, e2402327 (2024).","journal-title":"Adv. Sci."},{"key":"2924_CR238","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60717-z","volume":"14","author":"M Melzer","year":"2024","unstructured":"Melzer, M. et al. Differential Smad2\/3 linker phosphorylation is a crosstalk mechanism of Rho\/ROCK and canonical TGF-beta3 signaling in tenogenic differentiation. Sci. Rep. 14, 10393 (2024).","journal-title":"Sci. Rep."},{"key":"2924_CR239","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13046-023-02910-y","volume":"43","author":"C Feng","year":"2024","unstructured":"Feng, C. et al. A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt\/beta-catenin and modulates the immune cells. J. Exp. Clin. Cancer Res. 43, 9 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2924_CR240","doi-asserted-by":"publisher","first-page":"101510","DOI":"10.1016\/j.tranon.2022.101510","volume":"26","author":"D Fu","year":"2022","unstructured":"Fu, D. et al. Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities. Transl. Oncol. 26, 101510 (2022).","journal-title":"Transl. Oncol."},{"key":"2924_CR241","doi-asserted-by":"crossref","unstructured":"Huang, M. et al. Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci. Transl. Med. 12, eaay7522 (2020).","DOI":"10.1126\/scitranslmed.aay7522"},{"key":"2924_CR242","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01237-y","volume":"19","author":"C Zhou","year":"2020","unstructured":"Zhou, C. et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt\/beta-catenin and autophagy pathway through modulating the miR-619-5p\/Pygo2 and miR-619-5p\/ATG14 axes. Mol. Cancer 19, 118 (2020).","journal-title":"Mol. Cancer"},{"key":"2924_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110334","volume":"371","author":"M Purohit","year":"2023","unstructured":"Purohit, M. et al. Janus kinase\/signal transducers and activator of transcription (JAK\/STAT) and its role in Lung inflammatory disease. Chem. Biol. Interact. 371, 110334 (2023).","journal-title":"Chem. Biol. Interact."},{"key":"2924_CR244","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/carcin\/bgab075","volume":"42","author":"HE Sabaawy","year":"2021","unstructured":"Sabaawy, H. E., Ryan, B. M., Khiabanian, H. & Pine, S. R. JAK\/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis 42, 1411\u20131419 (2021).","journal-title":"Carcinogenesis"},{"key":"2924_CR245","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","volume":"26","author":"B Izar","year":"2020","unstructured":"Izar, B. et al. A single-cell landscape of high-grade serous ovarian cancer. Nat. Med. 26, 1271\u20131279 (2020).","journal-title":"Nat. Med."},{"key":"2924_CR246","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","volume":"3","author":"S Deng","year":"2022","unstructured":"Deng, S. et al. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat. Cancer 3, 1071\u20131087 (2022).","journal-title":"Nat. Cancer"},{"key":"2924_CR247","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-024-02962-8","volume":"43","author":"B Cheng","year":"2024","unstructured":"Cheng, B. et al. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1\/STAT4 pathway. J. Exp. Clin. Cancer Res. 43, 67 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2924_CR248","doi-asserted-by":"publisher","first-page":"111717","DOI":"10.1016\/j.intimp.2024.111717","volume":"130","author":"M Chen","year":"2024","unstructured":"Chen, M. & Wang, S. Preclinical development and clinical studies of targeted JAK\/STAT combined anti-PD-1\/PD-L1 therapy. Int Immunopharmacol. 130, 111717 (2024).","journal-title":"Int Immunopharmacol."},{"key":"2924_CR249","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41375-021-01315-0","volume":"35","author":"SB Patel","year":"2021","unstructured":"Patel, S. B. et al. Metabolic alterations mediated by STAT3 promotes drug persistence in CML. Leukemia 35, 3371\u20133382 (2021).","journal-title":"Leukemia"},{"key":"2924_CR250","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38581-8","volume":"14","author":"TL Wong","year":"2023","unstructured":"Wong, T. L. et al. ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer. Nat. Commun. 14, 2861 (2023).","journal-title":"Nat. Commun."},{"key":"2924_CR251","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1172\/JCI78185","volume":"125","author":"A Maraver","year":"2015","unstructured":"Maraver, A. et al. NOTCH pathway inactivation promotes bladder cancer progression. J. Clin. Investig. 125, 824\u2013830 (2015).","journal-title":"J. Clin. Investig."},{"key":"2924_CR252","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi, Q. et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct. Target Ther. 9, 128 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2924_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07324-y","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. TRIM59\/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway. Cell Death Dis. 15, 932 (2024).","journal-title":"Cell Death Dis."},{"key":"2924_CR254","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07723-9","volume":"16","author":"S Jiang","year":"2025","unstructured":"Jiang, S. et al. PRMT1-catalyzed NUSAP1 methylation enhances Notch2 signaling and 5-FU resistance in gastric cancer. Cell Death Dis. 16, 404 (2025).","journal-title":"Cell Death Dis."},{"key":"2924_CR255","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2417626122","volume":"122","author":"P Du","year":"2025","unstructured":"Du, P. et al. Intercellular contractile force attenuates chemosensitivity through Notch-MVP-mediated nuclear drug export. Proc. Natl. Acad. Sci. USA 122, e2417626122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2924_CR256","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.devcel.2022.06.006","volume":"57","author":"E Parmigiani","year":"2022","unstructured":"Parmigiani, E. et al. Interferon-gamma resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. Dev. Cell 57, 1847\u20131865.e1849 (2022).","journal-title":"Dev. Cell"},{"key":"2924_CR257","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31399-w","volume":"13","author":"MA Vittoria","year":"2022","unstructured":"Vittoria, M. A. et al. Inactivation of the Hippo tumor suppressor pathway promotes melanoma. Nat. Commun. 13, 3732 (2022).","journal-title":"Nat. Commun."},{"key":"2924_CR258","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1042\/BST20140030","volume":"42","author":"D Romano","year":"2014","unstructured":"Romano, D. et al. One Hippo and many masters: differential regulation of the Hippo pathway in cancer. Biochem. Soc. Trans. 42, 816\u2013821 (2014).","journal-title":"Biochem. Soc. Trans."},{"key":"2924_CR259","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr5683","volume":"11","author":"M Chatzifrangkeskou","year":"2025","unstructured":"Chatzifrangkeskou, M. et al. ATR-hippo drives force signaling to nuclear F-actin and links mechanotransduction to neurological disorders. Sci. Adv. 11, eadr5683 (2025).","journal-title":"Sci. Adv."},{"key":"2924_CR260","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300424","volume":"10","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. Hippo pathway activation in aged mesenchymal stem cells contributes to the dysregulation of hepatic inflammation in aged mice. Adv. Sci. 10, e2300424 (2023).","journal-title":"Adv. Sci."},{"key":"2924_CR261","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41568-023-00579-1","volume":"23","author":"JM Franklin","year":"2023","unstructured":"Franklin, J. M., Wu, Z. & Guan, K.-L. Insights into recent findings and clinical application of YAP and TAZ in cancer. Nat. Rev. Cancer 23, 512\u2013525 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2924_CR262","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2023114558","volume":"42","author":"Y Sun","year":"2023","unstructured":"Sun, Y. et al. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. EMBO J. 42, e114558 (2023).","journal-title":"EMBO J."},{"key":"2924_CR263","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07746-2","volume":"16","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. VCPIP1 facilitates pancreatic adenocarcinoma progression via Hippo\/YAP signaling. Cell Death Dis. 16, 422 (2025).","journal-title":"Cell Death Dis."},{"key":"2924_CR264","doi-asserted-by":"crossref","unstructured":"Kong, F. E. et al. Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci. Transl. Med. 13, eabb6282 (2021).","DOI":"10.1126\/scitranslmed.abb6282"},{"key":"2924_CR265","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2517376122","volume":"122","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Proteasome stress activates YAP\/TAZ through the RAP2-MAP4Ks-LATS1\/2 pathway and its therapeutic implications in solid tumors. Proc. Natl. Acad. Sci. USA 122, e2517376122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2924_CR266","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41575-021-00571-w","volume":"19","author":"JO Russell","year":"2022","unstructured":"Russell, J. O. & Camargo, F. D. Hippo signalling in the liver: role in development, regeneration and disease. Nat. Rev. Gastroenterol. Hepatol. 19, 297\u2013312 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2924_CR267","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","volume":"42","author":"Y Tang","year":"2023","unstructured":"Tang, Y., Zang, H., Wen, Q. & Fan, S. AXL in cancer: a modulator of drug resistance and therapeutic target. J. Exp. Clin. Cancer Res. 42, 148 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2924_CR268","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1136\/gutjnl-2021-325272","volume":"71","author":"G Bellomo","year":"2022","unstructured":"Bellomo, G. et al. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6\/AXL signalling axis. Gut 71, 2284\u20132299 (2022).","journal-title":"Gut"},{"key":"2924_CR269","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/cas.70006","volume":"116","author":"T Utsumi","year":"2025","unstructured":"Utsumi, T. et al. AXL-mediated drug resistance in ALK-rearranged NSCLC enhanced by GAS6 from macrophages and MMP11 positive fibroblasts. Cancer Sci. 116, 1034\u20131047 (2025).","journal-title":"Cancer Sci."},{"key":"2924_CR270","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","volume":"12","author":"A Noronha","year":"2022","unstructured":"Noronha, A. et al. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discov. 12, 2666\u20132683 (2022).","journal-title":"Cancer Discov."},{"key":"2924_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108853","volume":"210","author":"J Ancel","year":"2025","unstructured":"Ancel, J. et al. AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer. Lung Cancer 210, 108853 (2025).","journal-title":"Lung Cancer"},{"key":"2924_CR272","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.7150\/thno.15083","volume":"6","author":"C Wang","year":"2016","unstructured":"Wang, C. et al. Gas6\/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt\/GSK-3beta\/beta-catenin Signaling. Theranostics 6, 1205\u20131219 (2016).","journal-title":"Theranostics"},{"key":"2924_CR273","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/bjc.2016.428","volume":"116","author":"CM Gay","year":"2017","unstructured":"Gay, C. M., Balaji, K. & Byers, L. A. Giving AXL the axe: targeting AXL in human malignancy. Br. J. Cancer 116, 415\u2013423 (2017).","journal-title":"Br. J. Cancer"},{"key":"2924_CR274","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41401-024-01237-4","volume":"45","author":"R Han","year":"2024","unstructured":"Han, R. et al. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer. Acta Pharm. Sin. 45, 1264\u20131275 (2024).","journal-title":"Acta Pharm. Sin."},{"key":"2924_CR275","doi-asserted-by":"publisher","first-page":"110350","DOI":"10.1016\/j.cellsig.2022.110350","volume":"95","author":"S Daisy Precilla","year":"2022","unstructured":"Daisy Precilla, S., Biswas, I., Kuduvalli, S. S. & Anitha, T. S. Crosstalk between PI3K\/AKT\/mTOR and WNT\/beta-catenin signaling in GBM - Could combination therapy checkmate the collusion? Cell Signal. 95, 110350 (2022).","journal-title":"Cell Signal."},{"key":"2924_CR276","doi-asserted-by":"publisher","first-page":"109157","DOI":"10.1016\/j.celrep.2021.109157","volume":"35","author":"BN Kholodenko","year":"2021","unstructured":"Kholodenko, B. N., Rauch, N., Kolch, W. & Rukhlenko, O. S. A systematic analysis of signaling reactivation and drug resistance. Cell Rep. 35, 109157 (2021).","journal-title":"Cell Rep."},{"key":"2924_CR277","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-025-00511-3","volume":"11","author":"JL Gevertz","year":"2025","unstructured":"Gevertz, J. L. et al. Understanding therapeutic tolerance through a mathematical model of drug-induced resistance. NPJ Syst. Biol. Appl. 11, 30 (2025).","journal-title":"NPJ Syst. Biol. Appl."},{"key":"2924_CR278","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117880","volume":"183","author":"D Keresztes","year":"2025","unstructured":"Keresztes, D. et al. Cancer drug resistance as learning of signaling networks. Biomed. Pharmacother. 183, 117880 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"2924_CR279","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41586-022-05194-y","volume":"609","author":"OS Rukhlenko","year":"2022","unstructured":"Rukhlenko, O. S. et al. Control of cell state transitions. Nature 609, 975\u2013985 (2022).","journal-title":"Nature"},{"key":"2924_CR280","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.trecan.2024.09.011","volume":"10","author":"H Urra","year":"2024","unstructured":"Urra, H., Aravena, R., Gonzalez-Johnson, L. & Hetz, C. The UPRising connection between endoplasmic reticulum stress and the tumor microenvironment. Trends Cancer 10, 1161\u20131173 (2024).","journal-title":"Trends Cancer"},{"key":"2924_CR281","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/abbs\/gmab131","volume":"53","author":"M Yu","year":"2021","unstructured":"Yu, M. et al. Targeting UPR branches, a potential strategy for enhancing efficacy of cancer chemotherapy. Acta Biochim. Biophys. Sin. 53, 1417\u20131427 (2021).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"2924_CR282","first-page":"1106","volume":"2","author":"CG Cremers","year":"2019","unstructured":"Cremers, C. G. & Nguyen, L. K. Network rewiring, adaptive resistance and combating strategies in breast cancer. Cancer Drug Resist. 2, 1106\u20131126 (2019).","journal-title":"Cancer Drug Resist."},{"key":"2924_CR283","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101346","volume":"85","author":"L Gan","year":"2026","unstructured":"Gan, L. et al. A tumor-derived lactate\/ENO1 lactylation feedback loop facilitates osimertinib resistance of lung adenocarcinoma. Drug Resist. Updat. 85, 101346 (2026).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR284","doi-asserted-by":"publisher","first-page":"7998","DOI":"10.1021\/acs.jcim.4c01206","volume":"64","author":"J Yang","year":"2024","unstructured":"Yang, J. et al. Molecular mechanism-driven discovery of novel small molecule inhibitors against drug-resistant SARS-CoV-2 M(pro) variants. J. Chem. Inf. Model 64, 7998\u20138009 (2024).","journal-title":"J. Chem. Inf. Model"},{"key":"2924_CR285","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007511","volume":"16","author":"J Kim","year":"2020","unstructured":"Kim, J. et al. VAMPr: variant mapping and prediction of antibiotic resistance via explainable features and machine learning. PLoS Comput. Biol. 16, e1007511 (2020).","journal-title":"PLoS Comput. Biol."},{"key":"2924_CR286","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41196-8","volume":"14","author":"V Piskovsky","year":"2023","unstructured":"Piskovsky, V. & Oliveira, N. M. Bacterial motility can govern the dynamics of antibiotic resistance evolution. Nat. Commun. 14, 5584 (2023).","journal-title":"Nat. Commun."},{"key":"2924_CR287","doi-asserted-by":"crossref","unstructured":"Stohn, T. et al. Reconstructing and comparing signal transduction networks from single-cell protein quantification data. Bioinformatics. 42, btaf675 (2026).","DOI":"10.1093\/bioinformatics\/btaf675"},{"key":"2924_CR288","doi-asserted-by":"publisher","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","volume":"18","author":"AM Skoda","year":"2018","unstructured":"Skoda, A. M. et al. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn. J. Basic Med. Sci. 18, 8\u201320 (2018).","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"2924_CR289","doi-asserted-by":"publisher","first-page":"102389","DOI":"10.1016\/j.redox.2022.102389","volume":"54","author":"S Liu","year":"2022","unstructured":"Liu, S., Pi, J. & Zhang, Q. Signal amplification in the KEAP1-NRF2-ARE antioxidant response pathway. Redox Biol. 54, 102389 (2022).","journal-title":"Redox Biol."},{"key":"2924_CR290","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1172\/JCI130809","volume":"130","author":"MS Williams","year":"2020","unstructured":"Williams, M. S., Amaral, F. M., Simeoni, F. & Somervaille, T. C. A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia. J. Clin. Investig. 130, 1217\u20131232 (2020).","journal-title":"J. Clin. Investig."},{"key":"2924_CR291","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jid.2022.08.056","volume":"143","author":"U Radhakrishna","year":"2023","unstructured":"Radhakrishna, U. et al. Cytochrome P450 genes mediated by DNA methylation are involved in the resistance to hidradenitis suppurativa. J. Investig. Dermatol. 143, 670\u2013673.e619 (2023).","journal-title":"J. Investig. Dermatol."},{"key":"2924_CR292","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.7150\/thno.40566","volume":"10","author":"Q Meng","year":"2020","unstructured":"Meng, Q. et al. A miR-146a-5p\/TRAF6\/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Theranostics 10, 3967\u20133979 (2020).","journal-title":"Theranostics"},{"key":"2924_CR293","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412559","volume":"12","author":"R Dong","year":"2025","unstructured":"Dong, R. et al. Lactylation-driven HECTD2 limits the response of hepatocellular carcinoma to lenvatinib. Adv. Sci. 12, e2412559 (2025).","journal-title":"Adv. Sci."},{"key":"2924_CR294","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li, F. et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist. Updat. 68, 100938 (2023).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR295","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1159\/000491911","volume":"48","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. MicroRNA-374a inhibits aggressive tumor biological behavior in bladder carcinoma by suppressing Wnt\/beta-catenin signaling. Cell Physiol. Biochem 48, 815\u2013826 (2018).","journal-title":"Cell Physiol. Biochem"},{"key":"2924_CR296","doi-asserted-by":"publisher","first-page":"102756","DOI":"10.1016\/j.tice.2025.102756","volume":"93","author":"TDS Uchiya","year":"2025","unstructured":"Uchiya, T. D. S. et al. Resilience in adversity: exploring adaptive changes in cancer cells under stress. Tissue Cell 93, 102756 (2025).","journal-title":"Tissue Cell"},{"key":"2924_CR297","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505963","volume":"12","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Tumor small extracellular vesicle-transmitted LncRNA CATED promotes platinum-resistance in high-grade serous ovarian cancer. Adv. Sci. 12, e05963 (2025).","journal-title":"Adv. Sci."},{"key":"2924_CR298","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","volume":"41","author":"FJ de Miguel","year":"2023","unstructured":"de Miguel, F. J. et al. Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell 41, 1516\u20131534.e1519 (2023).","journal-title":"Cancer Cell"},{"key":"2924_CR299","doi-asserted-by":"crossref","unstructured":"Pang, L. et al. Epigenetic regulation of tumor immunity. J. Clin. Investig. 134, e178540 (2024).","DOI":"10.1172\/JCI178540"},{"key":"2924_CR300","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.cmet.2025.01.002","volume":"37","author":"NTB Nguyen","year":"2025","unstructured":"Nguyen, N. T. B. et al. Lactate controls cancer stemness and plasticity through epigenetic regulation. Cell Metab. 37, 903\u2013919.e910 (2025).","journal-title":"Cell Metab."},{"key":"2924_CR301","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34253-1","volume":"13","author":"H Ning","year":"2022","unstructured":"Ning, H. et al. Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. Nat. Commun. 13, 6578 (2022).","journal-title":"Nat. Commun."},{"key":"2924_CR302","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02198-2","volume":"24","author":"MA Freitas-Cortez","year":"2025","unstructured":"Freitas-Cortez, M. A. et al. Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins. Mol. Cancer 24, 40 (2025).","journal-title":"Mol. Cancer"},{"key":"2924_CR303","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai, W. et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct. Target Ther. 9, 332 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2924_CR304","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00701-x","volume":"12","author":"E Di Carlo","year":"2024","unstructured":"Di Carlo, E. & Sorrentino, C. State of the art CRISPR-based strategies for cancer diagnostics and treatment. Biomark. Res. 12, 156 (2024).","journal-title":"Biomark. Res."},{"key":"2924_CR305","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq9301","volume":"11","author":"J Wu","year":"2025","unstructured":"Wu, J. et al. Mitochondrial fatty acid oxidation regulates monocytic type I interferon signaling via histone acetylation. Sci. Adv. 11, eadq9301 (2025).","journal-title":"Sci. Adv."},{"key":"2924_CR306","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41590-024-02068-5","volume":"26","author":"J He","year":"2025","unstructured":"He, J. et al. The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer. Nat. Immunol. 26, 391\u2013403 (2025).","journal-title":"Nat. Immunol."},{"key":"2924_CR307","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2217\/fon-2020-1244","volume":"17","author":"E Julia","year":"2021","unstructured":"Julia, E. & Salles, G. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma. Future Oncol. 17, 2127\u20132140 (2021).","journal-title":"Future Oncol."},{"key":"2924_CR308","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","volume":"9","author":"J He","year":"2024","unstructured":"He, J. et al. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. Signal Transduct. Target Ther. 9, 209 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2924_CR309","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi, Z. D. et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct. Target Ther. 8, 113 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2924_CR310","doi-asserted-by":"crossref","unstructured":"Liu, T. et al. Transfer of damaged mitochondria from cancer cells to cancer-associated fibroblasts promotes tyrosine kinase inhibitor tolerance in EGFR-mutant lung cancer. Cancer Res. 86, 1215\u20131231 (2025).","DOI":"10.1158\/0008-5472.CAN-25-0433"},{"key":"2924_CR311","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s43018-023-00628-6","volume":"4","author":"X Zhou","year":"2023","unstructured":"Zhou, X. et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nat. Cancer 4, 1362\u20131381 (2023).","journal-title":"Nat. Cancer"},{"key":"2924_CR312","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00262-024-03882-4","volume":"74","author":"A Akli","year":"2025","unstructured":"Akli, A. et al. Role of the HGF\/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer Immunol. Immunother. 74, 58 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"2924_CR313","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02180-y","volume":"23","author":"X Zhou","year":"2024","unstructured":"Zhou, X. et al. THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer. Mol. Cancer 23, 282 (2024).","journal-title":"Mol. Cancer"},{"key":"2924_CR314","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05596-4","volume":"14","author":"K Chen","year":"2023","unstructured":"Chen, K. et al. Rab31 promotes metastasis and cisplatin resistance in stomach adenocarcinoma through Twist1-mediated EMT. Cell Death Dis. 14, 115 (2023).","journal-title":"Cell Death Dis."},{"key":"2924_CR315","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41556-022-01045-0","volume":"25","author":"J Cui","year":"2023","unstructured":"Cui, J. et al. MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state. Nat. Cell Biol. 25, 145\u2013158 (2023).","journal-title":"Nat. Cell Biol."},{"key":"2924_CR316","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"A Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga, A. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360\u2013371 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2924_CR317","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.710","volume":"5","author":"TC Dakal","year":"2024","unstructured":"Dakal, T. C. et al. Intricate relationship between cancer stemness, metastasis, and drug resistance. MedComm. 5, e710 (2024).","journal-title":"MedComm."},{"key":"2924_CR318","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2024.03.002","volume":"100","author":"AQ Khan","year":"2024","unstructured":"Khan, A. Q. et al. Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy. Semin. Cancer Biol. 100, 1\u201316 (2024).","journal-title":"Semin. Cancer Biol."},{"key":"2924_CR319","doi-asserted-by":"crossref","unstructured":"Chen, W. M. et al. QSOX2-mediated disulfide bond modification enhances tumor stemness and chemoresistance by activating TSC2\/mTOR\/c-Myc feedback loop in esophageal squamous cell carcinoma. Adv. Sci. 12, e00597 (2025).","DOI":"10.1002\/advs.202500597"},{"key":"2924_CR320","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. EGFR-TKIs induced DPP4 drives metabolic reprogramming of persister cells in lung cancer. Adv. Sci. 12, e06950 (2025).","DOI":"10.1002\/advs.202506950"},{"key":"2924_CR321","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman, S. K. et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 184, 226\u2013242.e221 (2021).","journal-title":"Cell"},{"key":"2924_CR322","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.CAN-22-2370","volume":"83","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells. Cancer Res. 83, 398\u2013413 (2023).","journal-title":"Cancer Res."},{"key":"2924_CR323","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564\u20131579 (2023).","journal-title":"Cell"},{"key":"2924_CR324","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cell.2024.03.021","volume":"187","author":"TW Battaglia","year":"2024","unstructured":"Battaglia, T. W. et al. A pan-cancer analysis of the microbiome in metastatic cancer. Cell 187, 2324\u20132335.e2319 (2024).","journal-title":"Cell"},{"key":"2924_CR325","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41423-023-00980-8","volume":"20","author":"Y Gu","year":"2023","unstructured":"Gu, Y., Zhang, Z. & Ten Dijke, P. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Cell Mol. Immunol. 20, 318\u2013340 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"2924_CR326","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.tips.2025.10.007","volume":"46","author":"C Cao","year":"2025","unstructured":"Cao, C. Neuron-tumor crosstalk fuels small cell lung cancer. Trends Pharm. Sci. 46, 1041\u20131043 (2025).","journal-title":"Trends Pharm. Sci."},{"key":"2924_CR327","doi-asserted-by":"crossref","unstructured":"Chen, D. et al. Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics. Mol Cancer. 25, 20 (2026).","DOI":"10.1186\/s12943-025-02555-9"},{"key":"2924_CR328","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12026-022-09267-y","volume":"70","author":"N Shi","year":"2022","unstructured":"Shi, N. et al. Research progress on drugs targeting the TGF-beta signaling pathway in fibrotic diseases. Immunol. Res. 70, 276\u2013288 (2022).","journal-title":"Immunol. Res."},{"key":"2924_CR329","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","volume":"74","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. Gut 74, 350\u2013363 (2025).","journal-title":"Gut"},{"key":"2924_CR330","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.tips.2024.09.006","volume":"45","author":"JT Low","year":"2024","unstructured":"Low, J. T., Ho, P. C. & Matsushita, M. TAM-tastic: from resistance to resilience in cancer. Trends Pharm. Sci. 45, 953\u2013954 (2024).","journal-title":"Trends Pharm. Sci."},{"key":"2924_CR331","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. npj Precis. Oncol. 8, 31 (2024).","journal-title":"npj Precis. Oncol."},{"key":"2924_CR332","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ccell.2022.08.012","volume":"40","author":"Q Shi","year":"2022","unstructured":"Shi, Q. et al. Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance. Cancer Cell 40, 1207\u20131222 e1210 (2022).","journal-title":"Cancer Cell"},{"key":"2924_CR333","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"2924_CR334","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm7269","volume":"17","author":"F Ma","year":"2025","unstructured":"Ma, F. et al. Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming. Sci. Transl. Med. 17, eadm7269 (2025).","journal-title":"Sci. Transl. Med."},{"key":"2924_CR335","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1158\/2159-8290.CD-24-0415","volume":"15","author":"R Trotta","year":"2025","unstructured":"Trotta, R. et al. Activated T cells break tumor immunosuppression by macrophage reeducation. Cancer Discov. 15, 1410\u20131436 (2025).","journal-title":"Cancer Discov."},{"key":"2924_CR336","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41416-021-01680-8","volume":"126","author":"B Darvishi","year":"2022","unstructured":"Darvishi, B., Eisavand, M. R., Majidzadeh, A. K. & Farahmand, L. Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance. Br. J. Cancer 126, 1253\u20131263 (2022).","journal-title":"Br. J. Cancer"},{"key":"2924_CR337","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash, J. & Shaked, Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 14, 1375\u20131388 (2024).","journal-title":"Cancer Discov."},{"key":"2924_CR338","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.trecan.2021.02.004","volume":"7","author":"E Pranzini","year":"2021","unstructured":"Pranzini, E. et al. Metabolic reprogramming in anticancer drug resistance: a focus on amino acids. Trends Cancer 7, 682\u2013699 (2021).","journal-title":"Trends Cancer"},{"key":"2924_CR339","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58429-7","volume":"16","author":"N Zhang","year":"2025","unstructured":"Zhang, N. et al. Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation. Nat. Commun. 16, 3177 (2025).","journal-title":"Nat. Commun."},{"key":"2924_CR340","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07646-5","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. USP9X integrates TGF-beta and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2alpha-maintained stemness. Cell Death Dis. 16, 312 (2025).","journal-title":"Cell Death Dis."},{"key":"2924_CR341","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","volume":"21","author":"JC Dawson","year":"2021","unstructured":"Dawson, J. C. et al. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer 21, 313\u2013324 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2924_CR342","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","volume":"3","author":"MM Tu","year":"2020","unstructured":"Tu, M. M. et al. Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Commun. Biol. 3, 720 (2020).","journal-title":"Commun. Biol."},{"key":"2924_CR343","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cac2.12629","volume":"45","author":"M Xu","year":"2025","unstructured":"Xu, M. et al. Advances in cervical cancer: current insights and future directions. Cancer Commun. (Lond.) 45, 77\u2013109 (2025).","journal-title":"Cancer Commun. (Lond.)"},{"key":"2924_CR344","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","volume":"357","author":"LT Geller","year":"2017","unstructured":"Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156\u20131160 (2017).","journal-title":"Science"},{"key":"2924_CR345","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nrgastro.2017.142","volume":"14","author":"H Thomas","year":"2017","unstructured":"Thomas, H. Pancreatic cancer: Intra-tumour bacteria promote gemcitabine resistance in pancreatic adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 14, 632 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2924_CR346","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.ccell.2023.09.012","volume":"41","author":"LE Colbert","year":"2023","unstructured":"Colbert, L. E. et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell 41, 1945\u20131962.e1911 (2023).","journal-title":"Cancer Cell"},{"key":"2924_CR347","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05728-y","volume":"615","author":"J Tintelnot","year":"2023","unstructured":"Tintelnot, J. et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168\u2013174 (2023).","journal-title":"Nature"},{"key":"2924_CR348","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2421710122","volume":"122","author":"G Qin","year":"2025","unstructured":"Qin, G. et al. A signaling molecule from intratumor bacteria promotes trastuzumab resistance in breast cancer cells. Proc. Natl. Acad. Sci. USA 122, e2421710122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2924_CR349","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.chom.2025.05.004","volume":"33","author":"X Ding","year":"2025","unstructured":"Ding, X. et al. Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. Cell Host Microbe 33, 941\u2013956.e910 (2025).","journal-title":"Cell Host Microbe"},{"key":"2924_CR350","first-page":"127","volume":"27","author":"Z-t Lv","year":"2020","unstructured":"Lv, Z. -t, Zhong, Y. -s, Chen, T. & Zhou, P. -h Research progress on mechanisms of fusobacterium nucleatum promoting colorectal cancer. Chin. J. Clin. Med. 27, 127\u2013131 (2020).","journal-title":"Chin. J. Clin. Med."},{"key":"2924_CR351","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/procel\/pwae005","volume":"15","author":"W Ma","year":"2024","unstructured":"Ma, W. et al. Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1. Protein Cell 15, 419\u2013440 (2024).","journal-title":"Protein Cell"},{"key":"2924_CR352","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1001\/jama.2025.2191","volume":"333","author":"E Fernandez","year":"2025","unstructured":"Fernandez, E., Wargo, J. A. & Helmink, B. A. The microbiome and cancer: a translational science review. JAMA 333, 2188\u20132196 (2025).","journal-title":"JAMA"},{"key":"2924_CR353","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s41564-024-01695-w","volume":"9","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice. Nat. Microbiol 9, 1467\u20131482 (2024).","journal-title":"Nat. Microbiol"},{"key":"2924_CR354","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/2326-6066.CIR-22-0541","volume":"11","author":"J Ren","year":"2023","unstructured":"Ren, J. et al. P. gingivalis infection upregulates PD-L1 expression on dendritic cells, suppresses CD8+ T-cell responses, and aggravates oral cancer. Cancer Immunol. Res. 11, 290\u2013305 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"2924_CR355","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1097\/HEP.0000000000000341","volume":"79","author":"AA Santos","year":"2024","unstructured":"Santos, A. A. et al. Spatial metabolomics and its application in the liver. Hepatology 79, 1158\u20131179 (2024).","journal-title":"Hepatology"},{"key":"2924_CR356","doi-asserted-by":"publisher","first-page":"e70024","DOI":"10.1002\/mco2.70024","volume":"5","author":"SE Qian","year":"2024","unstructured":"Qian, S. E. et al. Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targets. MedComm 5, e70024 (2024).","journal-title":"MedComm"},{"key":"2924_CR357","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50450-6","volume":"15","author":"CY Liao","year":"2024","unstructured":"Liao, C. Y. et al. Necroptosis enhances \u2018don\u2019t eat me\u2019 signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis. Nat. Commun. 15, 6043 (2024).","journal-title":"Nat. Commun."},{"key":"2924_CR358","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt8697","volume":"11","author":"H Gao","year":"2025","unstructured":"Gao, H. et al. Caspase-1-dependent pyroptosis converts alphaSMA(+) CAFs into collagen-III(high) iCAFs to fuel chemoresistant cancer stem cells. Sci. Adv. 11, eadt8697 (2025).","journal-title":"Sci. Adv."},{"key":"2924_CR359","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s41388-025-03337-9","volume":"44","author":"X Bai","year":"2025","unstructured":"Bai, X. et al. CBX3 promotes multidrug resistance by suppressing ferroptosis in colorectal carcinoma via the CUL3\/NRF2\/GPX2 axis. Oncogene 44, 1678\u20131693 (2025).","journal-title":"Oncogene"},{"key":"2924_CR360","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07498-z","volume":"16","author":"J Deng","year":"2025","unstructured":"Deng, J. et al. Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis. Cell Death Dis. 16, 193 (2025).","journal-title":"Cell Death Dis."},{"key":"2924_CR361","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100916","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist. Updat. 66, 100916 (2023).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR362","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ccell.2025.02.015","volume":"43","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Hypoxia inducible factor-1alpha drives cancer resistance to cuproptosis. Cancer Cell 43, 937\u2013954.e939 (2025).","journal-title":"Cancer Cell"},{"key":"2924_CR363","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41418-024-01341-2","volume":"31","author":"YT Liu","year":"2024","unstructured":"Liu, Y. T. et al. Dysregulated Wnt\/beta-catenin signaling confers resistance to cuproptosis in cancer cells. Cell Death Differ. 31, 1452\u20131466 (2024).","journal-title":"Cell Death Differ."},{"key":"2924_CR364","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101170","volume":"78","author":"X Niu","year":"2025","unstructured":"Niu, X. et al. Autophagy in cancer development, immune evasion, and drug resistance. Drug Resist. Updat. 78, 101170 (2025).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR365","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07057-y","volume":"15","author":"D Wang","year":"2024","unstructured":"Wang, D. et al. CircSEC24B activates autophagy and induces chemoresistance of colorectal cancer via OTUB1-mediated deubiquitination of SRPX2. Cell Death Dis. 15, 693 (2024).","journal-title":"Cell Death Dis."},{"key":"2924_CR366","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-023-02638-9","volume":"42","author":"Y Sun","year":"2023","unstructured":"Sun, Y. et al. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J. Exp. Clin. Cancer Res. 42, 65 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2924_CR367","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1080\/15548627.2025.2601865","volume":"22","author":"Y Dong","year":"2025","unstructured":"Dong, Y. et al. CCPG1-mediated reticulophagy promotes tumorigenesis and cisplatin resistance in bladder cancer. Autophagy 22, 586\u2013602 (2025).","journal-title":"Autophagy"},{"key":"2924_CR368","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41586-025-09745-x","volume":"649","author":"Y Zhang","year":"2026","unstructured":"Zhang, Y. et al. Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy. Nature 649, 1022\u20131031 (2026).","journal-title":"Nature"},{"key":"2924_CR369","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s13046-022-02485-0","volume":"41","author":"P Zheng","year":"2022","unstructured":"Zheng, P. et al. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. J. Exp. Clin. Cancer Res. 41, 271 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2924_CR370","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06486-3","volume":"23","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. & Wang, W. Advances in tumor subclone formation and mechanisms of growth and invasion. J. Transl. Med. 23, 461 (2025).","journal-title":"J. Transl. Med."},{"key":"2924_CR371","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s43018-022-00470-2","volume":"3","author":"F Cappellesso","year":"2022","unstructured":"Cappellesso, F. et al. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat. Cancer 3, 1464\u20131483 (2022).","journal-title":"Nat. Cancer"},{"key":"2924_CR372","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01524-w","volume":"21","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1\/P-gp mediated multi-drug resistance (MDR) in cancer cells. Mol. Cancer 21, 103 (2022).","journal-title":"Mol. Cancer"},{"key":"2924_CR373","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore, K. N. et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N. Engl. J. Med. 389, 2162\u20132174 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2924_CR374","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour, E. et al. Ponatinib vs imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA 331, 1814\u20131823 (2024).","journal-title":"JAMA"},{"key":"2924_CR375","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104500","volume":"90","author":"CL Hung","year":"2023","unstructured":"Hung, C. L. et al. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis targeting chimeras compound in castration resistant prostate cancer. EBioMedicine 90, 104500 (2023).","journal-title":"EBioMedicine"},{"key":"2924_CR376","doi-asserted-by":"crossref","unstructured":"Moon, Y., Jeon, S. I., Shim, M. K. & Kim, K. Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy. Pharmaceutics. 15, 411 (2023).","DOI":"10.3390\/pharmaceutics15020411"},{"key":"2924_CR377","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","volume":"3","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. An overview of PROTACs: a promising drug discovery paradigm. Mol. Biomed. 3, 46 (2022).","journal-title":"Mol. Biomed."},{"key":"2924_CR378","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen, A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet 401, 733\u2013746 (2023).","journal-title":"Lancet"},{"key":"2924_CR379","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N. Engl. J. Med 389, 2039\u20132051 (2023).","journal-title":"N. Engl. J. Med"},{"key":"2924_CR380","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04183-y","volume":"23","author":"A Lin","year":"2025","unstructured":"Lin, A. et al. Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors. BMC Med. 23, 341 (2025).","journal-title":"BMC Med."},{"key":"2924_CR381","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121\u20132132 (2023).","journal-title":"Nat. Med."},{"key":"2924_CR382","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51534-z","volume":"15","author":"ZY Han","year":"2024","unstructured":"Han, Z. Y. et al. Probiotics functionalized with a gallium-polyphenol network modulate the intratumor microbiota and promote anti-tumor immune responses in pancreatic cancer. Nat. Commun. 15, 7096 (2024).","journal-title":"Nat. Commun."},{"key":"2924_CR383","doi-asserted-by":"publisher","first-page":"31794","DOI":"10.1021\/acsnano.4c07000","volume":"18","author":"X Pang","year":"2024","unstructured":"Pang, X. et al. Targeted elimination of the oral pathogen to overcome chemoresistance of oral squamous cell carcinoma by biologically derived nanotherapeutics. ACS Nano 18, 31794\u201331808 (2024).","journal-title":"ACS Nano"},{"key":"2924_CR384","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410937","volume":"12","author":"W Zhang","year":"2025","unstructured":"Zhang, W. et al. RFWD3 reprograms nucleotide metabolism through PHGDH to induce chemoresistance in osteosarcoma. Adv. Sci. 12, e2410937 (2025).","journal-title":"Adv. Sci."},{"key":"2924_CR385","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07687-w","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu, H. et al. Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc\/ORC2 axis inhibition in non-small cell lung cancer. Cell Death Dis. 16, 356 (2025).","journal-title":"Cell Death Dis."},{"key":"2924_CR386","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews, L. P. et al. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity. Cell 187, 4355\u20134372.e4322 (2024).","journal-title":"Cell"},{"key":"2924_CR387","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo, A. R. et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity. Cell 187, 4373\u20134388 e4315 (2024).","journal-title":"Cell"},{"key":"2924_CR388","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27833-0","volume":"13","author":"Z Qi","year":"2022","unstructured":"Qi, Z. et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kalpha\/beta\/delta treatment. Nat. Commun. 13, 182 (2022).","journal-title":"Nat. Commun."},{"key":"2924_CR389","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer. Cancers 14, 5225 (2022).","DOI":"10.3390\/cancers14215225"},{"key":"2924_CR390","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv, J. et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study. Cancer Cell 42, 1401\u20131414.e1404 (2024).","journal-title":"Cancer Cell"},{"key":"2924_CR391","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2024.11.013","volume":"16","author":"MG Hirsch","year":"2025","unstructured":"Hirsch, M. G. et al. Stochastic modeling of single-cell gene expression adaptation reveals non-genomic contribution to evolution of tumor subclones. Cell Syst. 16, 101156 (2025).","journal-title":"Cell Syst."},{"key":"2924_CR392","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01968-5","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1816 (2017).","journal-title":"Nat. Commun."},{"key":"2924_CR393","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.actbio.2023.12.030","volume":"175","author":"Y Yu","year":"2024","unstructured":"Yu, Y. et al. Spatiotemporally controlled AuNPs@ZIF-8 based nanocarriers for synergistic photothermal\/chemodynamic therapy. Acta Biomater. 175, 317\u2013328 (2024).","journal-title":"Acta Biomater."},{"key":"2924_CR394","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202419892","volume":"35","author":"K Xu","year":"2025","unstructured":"Xu, K. et al. Fe2O3 hollow multishelled structure endowed temporal sequential mass release for apoptosis\/ferroptosis-induced combined cancer therapy. Adv. Funct. Mater. 35, 2419892 (2025).","journal-title":"Adv. Funct. Mater."},{"key":"2924_CR395","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106600","volume":"191","author":"S Saharkhiz","year":"2023","unstructured":"Saharkhiz, S. et al. A comparison study between doxorubicin and curcumin co-administration and co-loading in a smart niosomal formulation for MCF-7 breast cancer therapy. Eur. J. Pharm. Sci. 191, 106600 (2023).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2924_CR396","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr1728","volume":"11","author":"J Zhao","year":"2025","unstructured":"Zhao, J. et al. Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion. Sci. Adv. 11, eadr1728 (2025).","journal-title":"Sci. Adv."},{"key":"2924_CR397","doi-asserted-by":"publisher","first-page":"58203","DOI":"10.1021\/acsami.4c10336","volume":"16","author":"W Li","year":"2024","unstructured":"Li, W. et al. Trinity\u201d comprehensively regulates the tumor microenvironment of lipid-coated CaCO(3)@CuO(2) nanoparticles induces \u201ccuproptosis\u201d in HCC. ACS Appl. Mater. Interfaces 16, 58203\u201358216 (2024).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2924_CR398","doi-asserted-by":"publisher","first-page":"100956","DOI":"10.1016\/j.drup.2023.100956","volume":"68","author":"V Petrikaite","year":"2023","unstructured":"Petrikaite, V., D\u2019Avanzo, N., Celia, C. & Fresta, M. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models. Drug Resist. Updat. 68, 100956 (2023).","journal-title":"Drug Resist. Updat."},{"key":"2924_CR399","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-022-01280-w","volume":"15","author":"Y Han","year":"2022","unstructured":"Han, Y. et al. Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis. J. Hematol. Oncol. 15, 59 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2924_CR400","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","volume":"57","author":"A Franken","year":"2024","unstructured":"Franken, A. et al. CD4(+) T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy. Immunity 57, 541\u2013558.e547 (2024).","journal-title":"Immunity"},{"key":"2924_CR401","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41588-024-02036-7","volume":"57","author":"T Abay","year":"2025","unstructured":"Abay, T. et al. Transcript-specific enrichment enables profiling of rare cell states via single-cell RNA sequencing. Nat. Genet. 57, 451\u2013460 (2025).","journal-title":"Nat. Genet."},{"key":"2924_CR402","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107417","volume":"165","author":"D Cheng","year":"2023","unstructured":"Cheng, D. et al. Deciphering the heterogeneity and immunosuppressive function of regulatory T cells in osteosarcoma using single-cell RNA transcriptome. Comput Biol. Med. 165, 107417 (2023).","journal-title":"Comput Biol. Med."},{"key":"2924_CR403","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi, M. et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature 627, 221\u2013228 (2024).","journal-title":"Nature"},{"key":"2924_CR404","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/bloodadvances.2024014467","volume":"9","author":"W Mohammed Ismail","year":"2025","unstructured":"Mohammed Ismail, W. et al. Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory response. Blood Adv. 9, 402\u2013416 (2025).","journal-title":"Blood Adv."},{"key":"2924_CR405","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2025.100949","volume":"24","author":"J Woo","year":"2025","unstructured":"Woo, J. et al. Single-cell proteomic characterization of drug-resistant prostate cancer cells reveals molecular signatures associated with morphological changes. Mol. Cell Proteom. 24, 100949 (2025).","journal-title":"Mol. Cell Proteom."},{"key":"2924_CR406","doi-asserted-by":"publisher","first-page":"15028","DOI":"10.1021\/acs.analchem.5c00809","volume":"97","author":"Q-X Fan","year":"2025","unstructured":"Fan, Q.-X. et al. Integrated single-cell proteomic and morphometric analysis reveals heterogeneous drug-resistant subpopulations. Anal. Chem. 97, 15028\u201315037 (2025).","journal-title":"Anal. Chem."},{"key":"2924_CR407","doi-asserted-by":"publisher","first-page":"101740","DOI":"10.1016\/j.xcrm.2024.101740","volume":"5","author":"Y Du","year":"2024","unstructured":"Du, Y., Ding, X. & Ye, Y. The spatial multi-omics revolution in cancer therapy: Precision redefined. Cell Rep. Med. 5, 101740 (2024).","journal-title":"Cell Rep. Med."},{"key":"2924_CR408","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41588-024-01890-9","volume":"56","author":"C Shiau","year":"2024","unstructured":"Shiau, C. et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat. Genet. 56, 2466\u20132478 (2024).","journal-title":"Nat. Genet."},{"key":"2924_CR409","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.7150\/thno.102822","volume":"15","author":"L Ji","year":"2025","unstructured":"Ji, L. et al. Spatial metabolomics and transcriptomics reveal metabolic reprogramming and cellular interactions in nasopharyngeal carcinoma with high PD-1 expression and therapeutic response. Theranostics 15, 3035\u20133054 (2025).","journal-title":"Theranostics"},{"key":"2924_CR410","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","volume":"187","author":"J Pozniak","year":"2024","unstructured":"Pozniak, J. et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell 187, 166\u2013183.e125 (2024).","journal-title":"Cell"},{"key":"2924_CR411","doi-asserted-by":"crossref","unstructured":"Andersson-Rolf, A. & Clevers, H. New developments and applications of human organoids. Nat. Rev. Mol. Cell Biol. 27, 543\u2013558 (2026).","DOI":"10.1038\/s41580-026-00974-0"},{"key":"2924_CR412","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217106","volume":"598","author":"R Yang","year":"2024","unstructured":"Yang, R. et al. Drug-induced senescence by aurora kinase inhibitors attenuates innate immune response of macrophages on gastric cancer organoids. Cancer Lett. 598, 217106 (2024).","journal-title":"Cancer Lett."},{"key":"2924_CR413","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114098","volume":"158","author":"C Chai","year":"2023","unstructured":"Chai, C. et al. Targeting cancer drug resistance utilizing organoid technology. Biomed. Pharmacother. 158, 114098 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"2924_CR414","doi-asserted-by":"publisher","first-page":"15340","DOI":"10.1021\/acs.jmedchem.3c01400","volume":"66","author":"T Wu","year":"2023","unstructured":"Wu, T. et al. Discovery of selective and potent macrocyclic cdk9 inhibitors for the treatment of osimertinib-resistant non-small-cell lung cancer. J. Med. Chem. 66, 15340\u201315361 (2023).","journal-title":"J. Med. Chem."},{"key":"2924_CR415","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.32662","volume":"146","author":"J Shi","year":"2020","unstructured":"Shi, J., Li, Y., Jia, R. & Fan, X. The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance. Int J. Cancer 146, 2078\u20132088 (2020).","journal-title":"Int J. Cancer"},{"key":"2924_CR416","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41568-024-00779-3","volume":"25","author":"Z Blanchard","year":"2025","unstructured":"Blanchard, Z., Brown, E. A., Ghazaryan, A. & Welm, A. L. PDX models for functional precision oncology and discovery science. Nat. Rev. Cancer 25, 153\u2013166 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2924_CR417","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45796-w","volume":"15","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation. Nat. Commun. 15, 1871 (2024).","journal-title":"Nat. Commun."},{"key":"2924_CR418","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.intonc.2025.02.001","volume":"1","author":"J Gu","year":"2025","unstructured":"Gu, J. et al. Artificial intelligence in tumor drug resistance: mechanisms and treatment prospects. Intell. Oncol. 1, 73\u201388 (2025).","journal-title":"Intell. Oncol."},{"key":"2924_CR419","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02321-x","volume":"24","author":"Y Mao","year":"2025","unstructured":"Mao, Y. et al. Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges. Mol. Cancer 24, 123 (2025).","journal-title":"Mol. Cancer"},{"key":"2924_CR420","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1016\/j.apsb.2025.05.009","volume":"15","author":"X Long","year":"2025","unstructured":"Long, X. et al. Artificial intelligence and anti-cancer drugs\u2019 response. Acta Pharm. Sin. B 15, 3355\u20133371 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"2924_CR421","doi-asserted-by":"publisher","first-page":"170102","DOI":"10.1007\/s11432-024-4461-0","volume":"68","author":"R Qi","year":"2025","unstructured":"Qi, R. et al. AI in drug development: advances in response, combination therapy, repositioning, and molecular design. Sci. China Life Sci. 68, 170102 (2025).","journal-title":"Sci. China Life Sci."},{"key":"2924_CR422","doi-asserted-by":"publisher","first-page":"19645","DOI":"10.1021\/acs.jmedchem.5c01944","volume":"68","author":"H Lu","year":"2025","unstructured":"Lu, H. et al. Discovery of novel, potent, selective, and orally available dgkalpha inhibitors for the treatment of tumors. J. Med. Chem. 68, 19645\u201319660 (2025).","journal-title":"J. Med. Chem."},{"key":"2924_CR423","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ccell.2022.09.012","volume":"40","author":"J Lipkova","year":"2022","unstructured":"Lipkova, J. et al. Artificial intelligence for multimodal data integration in oncology. Cancer Cell 40, 1095\u20131110 (2022).","journal-title":"Cancer Cell"},{"key":"2924_CR424","doi-asserted-by":"publisher","first-page":"109302","DOI":"10.1016\/j.compbiomed.2024.109302","volume":"183","author":"M Tahir","year":"2024","unstructured":"Tahir, M. et al. Artificial intelligence and deep learning algorithms for epigenetic sequence analysis: a review for epigeneticists and AI experts. Comput. Biol. Med. 183, 109302 (2024).","journal-title":"Comput. Biol. Med."},{"key":"2924_CR425","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41746-025-01471-y","volume":"8","author":"E Fountzilas","year":"2025","unstructured":"Fountzilas, E. et al. Convergence of evolving artificial intelligence and machine learning techniques in precision oncology. npj Digit. Med. 8, 75 (2025).","journal-title":"npj Digit. Med."},{"key":"2924_CR426","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41401-022-00996-2","volume":"44","author":"J-h Gan","year":"2023","unstructured":"Gan, J. -h et al. DrugRep: an automatic virtual screening server for drug repurposing. Acta Pharm. Sin. 44, 888\u2013896 (2023).","journal-title":"Acta Pharm. Sin."},{"key":"2924_CR427","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.celrep.2015.08.014","volume":"12","author":"BN Kholodenko","year":"2015","unstructured":"Kholodenko, B. N. Drug resistance resulting from kinase dimerization is rationalized by thermodynamic factors describing allosteric inhibitor effects. Cell Rep. 12, 1939\u20131949 (2015).","journal-title":"Cell Rep."},{"key":"2924_CR428","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.dmpk.2024.101020","volume":"56","author":"M Oishi","year":"2024","unstructured":"Oishi, M. et al. Practical QSP application from the preclinical phase to enhance the probability of clinical success: Insights from case studies in oncology. Drug Metab. Pharmacokinet. 56, 101020 (2024).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"2924_CR429","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cell.2016.01.045","volume":"165","author":"B Zhao","year":"2016","unstructured":"Zhao, B. et al. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell 165, 234\u2013246 (2016).","journal-title":"Cell"},{"key":"2924_CR430","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41746-025-02198-6","volume":"9","author":"C Ma","year":"2025","unstructured":"Ma, C. et al. AI-driven virtual cell models in preclinical research: technical pathways, validation mechanisms, and clinical translation potential. npj Digit. Med. 9, 25 (2025).","journal-title":"npj Digit. Med."},{"key":"2924_CR431","doi-asserted-by":"crossref","unstructured":"Wan, J. C. M., Sasieni, P. & Rosenfeld, N. Promises and pitfalls of multi-cancer early detection using liquid biopsy tests. Nat. Rev. Clin. Oncol. 22, 566\u2013580 (2025).","DOI":"10.1038\/s41571-025-01033-x"},{"key":"2924_CR432","doi-asserted-by":"crossref","unstructured":"Bao, H. et al. Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nat. Med. 31, 2737\u20132745 (2025).","DOI":"10.1038\/s41591-025-03735-2"},{"key":"2924_CR433","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41586-025-09580-0","volume":"647","author":"MJ Williams","year":"2025","unstructured":"Williams, M. J. et al. Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA. Nature 647, 757\u2013765 (2025).","journal-title":"Nature"},{"key":"2924_CR434","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jtho.2024.07.008","volume":"19","author":"JE Gray","year":"2024","unstructured":"Gray, J. E. et al. Longitudinal analyses of circulating tumor DNA for the detection of egfr mutation-positive advanced NSCLC progression during treatment: data from FLAURA and AURA3. J. Thorac. Oncol. 19, 1525\u20131538 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"2924_CR435","doi-asserted-by":"crossref","unstructured":"Noji, R. et al. Dynamic changes in circulating tumor DNA during immunotherapy for head and neck cancer: SHIZUKU-HN study. Int. J. Mol. Sci. 26, 235 (2024).","DOI":"10.3390\/ijms26010235"},{"key":"2924_CR436","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41416-022-01699-5","volume":"126","author":"A Matikas","year":"2022","unstructured":"Matikas, A. et al. Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer. Br. J. Cancer 126, 1563\u20131569 (2022).","journal-title":"Br. J. Cancer"},{"key":"2924_CR437","doi-asserted-by":"publisher","first-page":"e2313017","DOI":"10.1001\/jamanetworkopen.2023.13017","volume":"6","author":"JA Mouabbi","year":"2023","unstructured":"Mouabbi, J. A. et al. Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw. Open 6, e2313017 (2023).","journal-title":"JAMA Netw. Open"},{"key":"2924_CR438","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s43018-024-00882-2","volume":"6","author":"R Wurth","year":"2025","unstructured":"Wurth, R. et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling. Nat. Cancer 6, 67\u201385 (2025).","journal-title":"Nat. Cancer"},{"key":"2924_CR439","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115646","volume":"427","author":"S Magnano","year":"2021","unstructured":"Magnano, S. et al. Cisplatin induces autophagy-associated apoptosis in human oral squamous cell carcinoma (OSCC) mediated in part through reactive oxygen species. Toxicol. Appl. Pharm. 427, 115646 (2021).","journal-title":"Toxicol. Appl. Pharm."},{"key":"2924_CR440","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/s41591-025-04093-9","volume":"31","author":"BV Landon","year":"2025","unstructured":"Landon, B. V. et al. Liquid biopsies across the cancer care continuum. Nat. Med. 31, 4006\u20134021 (2025).","journal-title":"Nat. Med."},{"key":"2924_CR441","doi-asserted-by":"crossref","unstructured":"Rojas-Salazar, Y. L., Gomez-Montanez, E. & Rojas-Salazar, J. G. Liquid biopsy in modern oncology: advances, challenges, and future perspectives in early cancer detection, minimal residual disease, and dynamic patient monitoring. Curr. Oncol. Rep. 28, 59 (2026).","DOI":"10.1007\/s11912-026-01799-y"},{"key":"2924_CR442","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309422","volume":"11","author":"T Peng","year":"2024","unstructured":"Peng, T. et al. Plasma cell-free DNA concentration and fragmentomes predict neoadjuvant chemotherapy response in cervical cancer patients. Adv. Sci. 11, 2309422 (2024).","journal-title":"Adv. Sci."},{"key":"2924_CR443","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41422-023-00909-w","volume":"34","author":"LP Ge","year":"2024","unstructured":"Ge, L. P. et al. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell Res. 34, 58\u201375 (2024).","journal-title":"Cell Res."},{"key":"2924_CR444","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-022-00741-7","volume":"19","author":"R Baron","year":"2023","unstructured":"Baron, R. et al. Maximizing treatment efficacy through patient stratification in neuropathic pain trials. Nat. Rev. Neurol. 19, 53\u201364 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"2924_CR445","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","volume":"177","author":"J Wagner","year":"2019","unstructured":"Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330\u20131345.e1318 (2019).","journal-title":"Cell"},{"key":"2924_CR446","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"2924_CR447","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder, A. M. et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat. Rev. Cancer 24, 498\u2013512 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2924_CR448","doi-asserted-by":"crossref","unstructured":"Long, G. V. et al. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D\/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. J. Immunother. Cancer. 13, e012034 (2025).","DOI":"10.1136\/jitc-2025-012034"},{"key":"2924_CR449","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1038\/s41591-025-03802-8","volume":"31","author":"MD Galsky","year":"2025","unstructured":"Galsky, M. D. et al. Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial. Nat. Med. 31, 3062\u20133073 (2025).","journal-title":"Nat. Med."},{"key":"2924_CR450","doi-asserted-by":"crossref","unstructured":"Tang, L. B. et al. Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer. Nat. Rev. Clin. Oncol. 22, 546\u2013565 (2025).","DOI":"10.1038\/s41571-025-01029-7"},{"key":"2924_CR451","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","volume":"10","author":"EA Kuczynski","year":"2013","unstructured":"Kuczynski, E. A., Sargent, D. J., Grothey, A. & Kerbel, R. S. Drug rechallenge and treatment beyond progression\u2013implications for drug resistance. Nat. Rev. Clin. Oncol. 10, 571\u2013587 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2924_CR452","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1440-1843.2006.00794.x","volume":"11","author":"T Seto","year":"2006","unstructured":"Seto, T. et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology 11, 113\u2013116 (2006).","journal-title":"Respirology"},{"key":"2924_CR453","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","volume":"25","author":"Y Lv","year":"2025","unstructured":"Lv, Y. et al. Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors. Clin. Exp. Med. 25, 139 (2025).","journal-title":"Clin. Exp. Med."},{"key":"2924_CR454","doi-asserted-by":"publisher","first-page":"e10677","DOI":"10.1002\/btm2.10677","volume":"9","author":"E Udofa","year":"2024","unstructured":"Udofa, E., Sankholkar, D., Mitragotri, S. & Zhao, Z. Antibody drug conjugates in the clinic. Bioeng. Transl. Med. 9, e10677 (2024).","journal-title":"Bioeng. Transl. Med."},{"key":"2924_CR455","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62\u201370 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2924_CR456","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdw413","volume":"28","author":"LA Renfro","year":"2017","unstructured":"Renfro, L. A. & Sargent, D. J. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann. Oncol. 28, 34\u201343 (2017).","journal-title":"Ann. Oncol."},{"key":"2924_CR457","doi-asserted-by":"publisher","first-page":"1266286","DOI":"10.3389\/fonc.2023.1266286","volume":"13","author":"A Kasim","year":"2023","unstructured":"Kasim, A. et al. Basket trials in oncology: a systematic review of practices and methods, comparative analysis of innovative methods, and an appraisal of a missed opportunity. Front. Oncol. 13, 1266286 (2023).","journal-title":"Front. Oncol."},{"key":"2924_CR458","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70028","volume":"4","author":"S Li","year":"2025","unstructured":"Li, S. et al. Re-innovation in clinical trial designs based on precision therapy. Cancer Innov. 4, e70028 (2025).","journal-title":"Cancer Innov."},{"key":"2924_CR459","doi-asserted-by":"publisher","first-page":"202","DOI":"10.12793\/tcp.2023.31.e21","volume":"31","author":"H Lee","year":"2023","unstructured":"Lee, H. et al. Adaptive design clinical trials: current status by disease and trial phase in various perspectives. Transl. Clin. Pharm. 31, 202\u2013216 (2023).","journal-title":"Transl. Clin. Pharm."},{"key":"2924_CR460","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1016\/j.cell.2025.07.042","volume":"188","author":"E Grist","year":"2025","unstructured":"Grist, E. et al. Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. Cell 188, 5717\u20135734.e5710 (2025).","journal-title":"Cell"},{"key":"2924_CR461","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.annonc.2023.08.008","volume":"34","author":"MAR Strobl","year":"2023","unstructured":"Strobl, M. A. R. et al. Treatment of evolving cancers will require dynamic decision support. Ann. Oncol. 34, 867\u2013884 (2023).","journal-title":"Ann. Oncol."},{"key":"2924_CR462","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41588-025-02204-3","volume":"57","author":"K Zhao","year":"2025","unstructured":"Zhao, K. et al. Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination. Nat. Genet. 57, 1504\u20131511 (2025).","journal-title":"Nat. Genet."},{"key":"2924_CR463","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s10555-021-09969-z","volume":"40","author":"S Giunta","year":"2021","unstructured":"Giunta, S. Decoding human cancer with whole genome sequencing: a review of PCAWG project studies published in February 2020. Cancer Metastasis Rev. 40, 909\u2013924 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"2924_CR464","doi-asserted-by":"crossref","unstructured":"Garg, P. et al. Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers 16, 2478 (2024).","DOI":"10.3390\/cancers16132478"},{"key":"2924_CR465","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1016\/j.cell.2024.09.012","volume":"187","author":"CR Walker","year":"2024","unstructured":"Walker, C. R. et al. Private information leakage from single-cell count matrices. Cell 187, 6537\u20136549.e6510 (2024).","journal-title":"Cell"},{"key":"2924_CR466","doi-asserted-by":"publisher","first-page":"1473125","DOI":"10.3389\/fphys.2024.1473125","volume":"15","author":"S Kemkar","year":"2024","unstructured":"Kemkar, S. et al. Towards verifiable cancer digital twins: tissue level modeling protocol for precision medicine. Front. Physiol. 15, 1473125 (2024).","journal-title":"Front. Physiol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02924-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02924-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02924-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:02:32Z","timestamp":1785715352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02924-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":466,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2924"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02924-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"307"}}